Note: Descriptions are shown in the official language in which they were submitted.
WO 2015/042705
PCT/CA2014/050915
INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES
THEREOF
FIELD OF INVENTION
[0001] The present invention relates to interleukin-4 receptor-binding protein
fusions.
More specifically, the invention provides, in part, fusion proteins that
include an
interleukin-4 or interleukin-13 protein moiety joined to a pro-apoptotic Bc1-2
family
member protein moiety.
BACKGROUND OF THE INVENTION
[0002] Interleukin-4 (IL-4) is a pleiotropic cytokine produced by activated T
cells, and is
the ligand for the IL-4 receptor (IL-4R), which can also bind to interleukin-
13 (IL-13). IL-
4, like many cytokines, first binds to a high-affinity receptor chain
(designated "a"),
followed by binding of the IL-4-a chain complex with a second low-affinity
receptor chain
designated "yc". Therefore, the primary binding chain for IL-4 is the IL-4
receptor alpha
(IL-4Ra), which binds with high affinity (KD = ¨10-10 M). The IL-4/IL-4Ra
complex can
then bind the second component of the IL-4 receptor, 7c (the "Type I"
receptor) with
relatively low affinity. Additionally, the IL-411L-4Ra complex can also bind
the
interleukin-13 (IL-13) receptor al (IL-13R al) (the "Type II" receptor).
[0003] Different cell types express different amounts of the Type I and Type
II receptor
chains. For example, while IL-4Ra is present on most cells, yc is generally
expressed on
hematopoietic cells and IL-13R al is generally expressed on non-hematopoietic
cells.
Accordingly, 7c, but not IL-13R al, is found on T cells, natural killer (NK)
cells,
basophils, mast cells, and most mouse B cells (most human B cells express both
yc and IL-
13R al).
[0004] Some bone marrow-derived cells, including macrophages and dendritic
cells,
express both 7c and IL-13R al and consequently respond to both IL-4 and IL-13.
IL-13R
al, but little or no 7c, is found on most non-bone marrow-derived cells,
including smooth
muscle and epithelial cells.
[0005] Variant IL-4 molecules having differential selectivities for Type I and
Type II
receptors have been proposed (Junttila et al. Nature Chemical Biology 8:990-
998, 2012.)
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
[0006] Circularly permuted molecules are those in which the termini of a
linear molecule
(e.g., ligand) have been joined together, either directly or via a linker, to
produce a circular
molecule, after which the circular molecule is opened at another location to
produce a new
linear molecule with termini different from the termini of the original
molecule. Circularly
permuted variants of IL-4 have been described in, for example, U.S. Patent No.
6,011,002,
issued January 4, 2000, to Pastan et al.
[0007] Programmed cell death or "apoptosis," is a common phenomenon in the
development of animal cells and is both positively and negatively regulated.
In addition to
its involvement in neuronal and lymphoid system development and overall cell
population
homeostasis, apoptosis also plays a significant role in various diseases and
injuries
resulting from aberrant regulation of apoptotic pathways. For example,
aberrant activation
of neuronal cell death by apoptosis has been implicated in many
neurodegenerative
diseases and conditions, such as Alzheimer disease (Barinaga, Science 281:1303-
1304),
Huntington's disease, spinal-muscular atrophy, neuronal damage caused during
stroke
(reviewed in Rubin, British Med. Bulle., 53(3):617-631, 1997; and Barinaga,
Science
281:1302-1303), transient ischemic neuronal injury (e.g., spinal cord injury),
etc.
Conversely, aberrant suppression of apoptosis can result in hyperproliferation
of cells,
leading to cancer and other hyperproliferative disorders.
[0008] Apoptosis is regulated by a number of proteins, including members of
the Bc1-2
family. Bc1-2 was one of the first proteins identified as regulating apoptosis
(Cleary et al.,
Cell 47:19-28, 1986; Tsujimoto and Croce, Proc. Natl. Acad. Sci. USA 83:5214-
5218,
1986). Since its discovery, several Bc1-2-related proteins ("Bc1-2 family
proteins" or "Bcl-
2 family members") have been identified as regulators of apoptosis (White,
Genes Dev.
10:1-15, 1996; Yang et al., Cell 80:285-291, 1995; Lomonosova, E. and G.
Chinnadurai,
Oncogene 27, S2¨S19, 2009).
[0009] Several therapeutic agents for treatment of neurodegenerative diseases,
cancer, etc.
have been explored but exhibit limitations that restrict their use in the
clinic. For example,
many chemotherapeutic agents act by inducing apoptosis in proliferating
neoplastic cells,
but their therapeutic value is limited by the extent to which they are toxic
to normal cells.
Treatment with standard apoptosis inhibitory molecules, for instance peptide-
type caspase
2
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
inhibitors (e.g., DEVD-type), has proven unsatisfactory for clinical work due
to low
membrane permeability of these inhibitors.
[0010] Targeted immunotoxins (genetic or biochemical fusions between a toxic
molecule,
for instance a bacterial toxin, and a targeting domain derived, typically from
an antibody
molecule) have been proposed in attempts to selectively eliminate cancer
cells. For
example, diphtheria toxin (DT) variants have been generated and tested for
their ability to
selectively kill cancer cells (Thorpe et al., Nature 271:752-755, 1978; Laske
et al., Nature
Medicine 3:1362-1368, 1997). Similarly, Pseudomonas exotoxin (PE) fusion
proteins
have been investigated as potential cancer therapeutics (Kreitman and Pastan,
Blood
90:252-259, 1997; Shimamura et al. Cancer Res. 67:9903-9912; 2007).
SUMMARY OF THE INVENTION
[0011] The present invention relates to interleukin-4 receptor binding fusion
proteins.
More specifically, the invention provides, in part, fusion proteins that
include a interleukin-
4 receptor-binding protein moiety joined to a pro-apoptotic Bc1-2 family
member protein
moiety and uses thereof.
[0012] In one aspect, the invention provides a fusion protein including a
interleukin-4 (IL-
4) receptor binding protein and a pro-apoptotic Bc1-2 family polypeptide. In
some
embodiments, the IL-4 receptor binding protein may be circularly permuted
(cp). In some
embodiments, the Bc1-2 family polypeptide may be a pro-apoptotic Bc1-2 family
polypeptide comprising a BH3 domain (such as Bad, Bik/Nbk, Bid, Bim/Bod, Hrk,
Bak or
Bax). The BH3 domain may further include a mutation that reduces
phosphorylation. The
pro-apoptotic Bc1-2 family polypeptide including a BH3 domain that further
includes a
mutation that reduces phosphorylation may be a Bad polypeptide. The fusion
protein may
be capable of inhibiting cell survival, inhibiting cell proliferation, or
enhancing cell death
or apoptosis of a target cell expressing an IL-4R.
[0013] In some embodiments, the IL-4 receptor binding protein may be a mutant
IL-4 or
IL-13 selective for binding to a Type I or a Type II IL-4 receptor (IL-4R).
The mutant IL-
4 selective for binding to a Type II IL-4R may include a KFR variant or a KF
variant. The
mutant 1L-4 selective for binding to a Type I IL-4R may include an RGA
variant. The
mutant IL-13 may be an All variant or a DN variant.
3
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
[0014] In some embodiments, the fusion protein may further include a linker.
The linker
may have the sequence GS or may be a ubiquitin or ubiquitin variant molecule.
The fusion
protein may include the sequence set forth in SEQ ID NOs: 24-27.
[0015] In some aspects, there is provided a nucleic acid molecule encoding a
fusion
protein as described herein, or a vector including the nucleic acid molecule,
or a host cell
including the vector. In some aspects, there is provided a nucleic acid
molecule encoding a
fusion protein as set forth in SEQ ID NOs: 24-27 or comprising SEQ ID NOs: 35-
38.
[0016] In some aspects, there is provided a pharmaceutical composition
including a fusion
protein as described herein, a nucleic acid molecule encoding the fusion
protein, or a
vector including the nucleic acid molecule, or a host cell including the
vector.
[0017] In some aspects, there is provided a method of inducing cell death by
administering
a fusion protein including a pro-apoptotic Bc1-2 family polypeptide, a nucleic
acid
molecule encoding the fusion protein, or a vector including the nucleic acid
molecule, or a
host cell including the vector, to a subject in need thereof.
[0018] In some aspects, there is provided a method of inducing cell death by
contacting a
target cell that expresses an IL-4R with a fusion protein including a pro-
apoptotic Bc1-2
family polypeptide, a nucleic acid molecule encoding the fusion protein, or a
vector
including the nucleic acid molecule.
[0019] In some aspects, there is provided a method of treating cancer by
administering: a
fusion protein including a pro-apoptotic Bc1-2 family polypeptide, a nucleic
acid molecule
encoding the fusion protein, or a vector including the nucleic acid molecule,
or a host cell
including the vector, to a subject in need thereof.
[0020] In some aspects, there is provided a method of treating cancer by
contacting a
neoplastic cell that expresses an IL-4R with a fusion protein including a pro-
apoptotic Bcl-
2 family polypeptide, a nucleic acid molecule encoding the fusion protein, or
a vector
including the nucleic acid molecule.
[0021] In some aspects, there is provided a method of treating cancer by
contacting a non-
malignant cell that expresses an IL-4R in a tumour microenvironment in a
subject in need
thereof with a fusion protein including a pro-apoptotic Bc1-2 family
polypeptide, a nucleic
4
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
acid molecule encoding the fusion protein, or a vector including the nucleic
acid molecule.
In some embodiments, the non-malignant cell is contacted prior to the subject
starting a
therapy.
[0022] In some aspects, there is provided a method of treating a
hyperproliferative or
differentiative disorder by administering a fusion protein including a pro-
apoptotic Bc1-2
family polypeptide, a nucleic acid molecule encoding the fusion protein, or a
vector
including the nucleic acid molecule to a subject in need thereof. The
hyperproliferative or
differentiative disorder may be a fibrosis or hyperplasia, an inflammatory
conditions or an
autoimmune condition. The fibrosis or hyperplasia may be pulmonary fibrosis or
hyperplasia (such as benign prostatic hyperplasia), cardiac fibrosis, or liver
fibrosis; the
inflammatory condition may be prostatitis, vernal keratoconjunctivitis,
artherosclerosis, or
idiopathic pulmonary pneumonia; or the autoimmune condition may be Graves
disease.
[0023] In some aspects, there is provided a use of a fusion protein including
a pro-
apoptotic Bc1-2 family polypeptide, a nucleic acid molecule encoding the
fusion protein, or
a vector including the nucleic acid molecule for inducing cell death or
treating cancer or
treating a hyperproliferative or differentiative disorder in a subject in need
thereof.
[0024] In various embodiments of the alternative aspects, the subject may be a
human.
[0025] This summary does not necessarily describe all features of the
invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0026] These and other features of the invention will become more apparent
from the
following description in which reference is made to the appended drawings
wherein:
[0027] Figure 1 is an illustration of a cpIL-4BAD (cpIL-4g:s-BADaa) in a pET
24a
expression vector;
[0028] Figure 2 is a graph showing the effect of cp1L-4BAD (cpIL-4BADaa) on IL-
4Ra
positive tumor cell (U 251) viability;
[0029] Figure 3 is a graph showing the effect of cpIL-4BAD (cpIL-4BADaa)
(squares) on
IL-4Ra positive tumor cell (U 251) viability in the presence of excess IL-4
(triangles);
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
[0030] Figure 4 is a graph showing the effect of cp1L-4BAD (cpIL-4BADaa) on IL-
4Ra
positive tumor cell (Daudi cell) viability;
[0031] Figure 5 is a graph showing the effect of cpIL-4BAD (cpIL-4BADaa)
(triangles)
on IL-4Ra positive tumor cell Daudi viability in the presence of excess IL-4
(squares);
[0032] Figure 6 is a graph showing the effect of cp1L-4BAD (cp1L-4BADaa) on
the
colony number of IL-4Ra positive tumor cells (U 251);
[0033] Figure 7 is a graph showing the effect of intratumoural (squares) and
intraperitoneal (triangles) injection of cpIL-4BAD fusion protein in athymic
mice after the
development of subcutaneous glioma tumors with U 251 tumor cells (circles =
controls);
[0034] Figure 8 is a graph showing the survival of cpIL-4BAD-treated mice
(intratumoural injection group = open diamonds, intraperitoneal injection
group ¨
triangles, controls = solid diamonds);
[0035] Figure 9 shows an illustration of a pGW07 E. coli expression vector;
[0036] Figures 10A-F show the nucleic acid (SEQ ID NOs: 29, 30 and 32) and
amino
sequences (SEQ ID NOs: 18, 19 and 21) of IL-4BAD (A-B), cpIL-4BAD (C-D) and
cpS4-
BAD (E-F) fusion constructs;
[0037] Figures 11A-B show the nucleic acid (A; SEQ ID NO: 37) and amino
sequence (B;
SEQ ID NO: 26) of a pKFR4-BAD-H6 fusion construct.
DETAILED DESCRIPTION
[0038] The present disclosure provides, in part, a fusion protein including an
IL-4R
binding protein joined to a pro-apoptotic Bc1-2 family protein and uses
thereof
[0039] IL-4R Binding Proteins
[0040] IL-4R binding proteins include IL-4 and IL-13.
[0041] IL-4 proteins or IL-4 "protein moieties" include native IL-4 proteins,
as well as
variant IL-4 proteins. A "native" or "wild type" IL-4 sequence, as used
herein, refers to a
human IL-4 sequence, whether purified from natural sources or made using
recombinant
techniques, and including the amino acid sequence (with an additional
methionine at the
6
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
N-terminus) as follows:
MHKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKNTTEKETFCRAATVLRQFY
SHHEKDTRCLGATAQQFHRHKQURFLKRLDRNLWGLAGLNSCPVKEANQSTLE
NFLERLKTIMREKYSKCSS (SEQ ID NO: 1).
100421 Alternative human IL-4 sequences include the amino acid sequence (with
an
additional methionine at the N-terminus) as follows:
MHKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKDTTEKETFCRAATVLRQFY
SHHEKDIRCLGATAQQFHRHKOLIRFLKRLDRNLWGLAGLNSCPVKEANQSTLE
NFLERLKTIMREKYSKCSS (SEQ ID NO: 2).
[0043] In some embodiments, IL-4 proteins that can be used in the fusion
proteins of the
present disclosure are variant IL-4 proteins that have increased selectivity
for 7c (Type I
receptor) relative to IL-13R al (Type II receptor) or vice versa as described,
for example,
in Junttila et al. (Nature Chemical Biology 8:990-998, 2012). In some
embodiments, a
variant IL-4 protein that has increased selectivity for 7c (Type I receptor)
is an IL-4 protein
that includes the following mutations relative to the sequence of native human
IL-4 (e.g.,
SEQ ID NO: 1) or an alternative IL-4 sequence (e.g., SEQ ID NO:2), the
numbering
excluding the methionine at the N-terminus: R121Q/Y124W/S125F (the "RGA" or
"super-
4" or "S4" variant) as described, for example, in Junttila et al. (Nature
Chemical Biology
8:990-998, 2012).
[0044] In some embodiments, a variant IL-4 protein that has increased
selectivity for IL-
13R al (Type II receptor) is an IL-4 protein that includes the following
mutations relative
to the sequence of native human IL-4 (e.g., SEQ ID NO: 1) or an alternative IL-
4 sequence
(e.g., SEQ ID NO:2), the numbering excluding the methionine at the N-terminus:
R121K/Y124F/S125R (the "KFR" or "KFR4" variant) or R121K/Y124F (the "K.F"
variant).
[0045] In some embodiments, IL-4 proteins that can be used in the fusion
proteins of the
present disclosure are circularly permuted (cp), as described in, for example,
U.S. Patent
No. 6,011,002, issued January 4, 2000, to Pastan etal. In some embodiments, a
cpIL-4
protein that can be used in the fusion proteins of the present disclosure
includes an IL-4
protein in which residues 38-129 of native human IL-4 (e.g., SEQ ID NO: 1) or
an
7
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
alternative IL-4 sequence (e.g., SEQ ID NO:2), the numbering excluding the
methionine at
the N-terminus, are joined to residues 1-37 with a GGNGG linker and an initial
methionine
residue, as follows:
MDTTEKETFCRAATVLRQFYSHHEKDIRCLGATAQQFHRHKQURFLKRLDRNL
WGLAGLNSCPVKEANQSTLENFLERLKTIMREKYSKCSSGGNGGHKCDITLQEII
KTLNSLTEQKTLCTELTVTDIFAAS (SEQ ID NO: 3).
[0046] In alternative embodiments, a cpIL-4 protein that can be used in the
fusion proteins
of the present disclosure includes an IL-4 protein in which residues 38-129 of
native
human IL-4 (e.g., SEQ ID NO: 1) or an alternative IL-4 sequence (e.g., SEQ ID
NO:2), the
numbering excluding the methionine at the N-terminus, are joined to residues 1-
37 with a
GGNGG linker and an initial methionine residue, in the context of an "RGA" or
"super-4"
or "S4" variant, as follows:
MDTTEKETFCRAATVLRQFYSHHEKDIRCLGATAQQFHRHKQURFLKRLDRNL
WG LAGLNSCPVKEANQSTLEN F LERLRVI MOKWFKCGAGGNGGH KC D ITLQE I
IKTLNSLTEQKTLCTELTVTDIFAAS (SEQ ID NO: 4).
[0047] In alternative embodiments, a cpIL-4 protein that can be used in the
fusion proteins
of the present disclosure includes an IL-4 protein in which residues 38-129 of
native
human IL-4 (e.g., SEQ ID NO: 1) or an alternative IL-4 sequence (e.g., SEQ ID
NO:2), the
numbering excluding the methionine at the N-terminus, are joined to residues 1-
37 with a
GGNGG linker and an initial methionine residue, in the context of a "KFR"
variant, as
follows:
MDTTEKETFCRAATVLRQFYSHHEKDIRCLGATAQQFHRHKOLIRFLKRLDRNL
WGLAGLNSCPVKEANQSTLENFLERLKTIMKEKFRKCSSGGNGGHKCDITLQEII
KTLNSLTEQKTLCTELTVTDIFAAS (SEQ ID NO: 5).
[0048] In alternative embodiments, a cpIL-4 protein that can be used in the
fusion proteins
of the present disclosure includes an IL-4 protein in which residues 38-129 of
native
human IL-4 (e.g., SEQ ID NO: 1) or an alternative IL-4 sequence (e.g., SEQ ID
NO:2), the
numbering excluding the methionine at the N-terminus, are joined to residues 1-
37 with a
GGNGG linker and an initial methionine residue, in the context of a "KF"
variant, as
follows:
8
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
MDTTEKETFCRAATVLRQFYSHHEKDIRCLGATAQQFHRHKQURFLKRLDRNL
WGLAGLNSCPVKEANQSTLENFLERLKTIMKEKFKCSSGGNGGHKCDITLQEIIK
TLNSLTEQKTLCTELTVTDIFAAS (SEQ ID NO: 6).
100491 In alternative embodiments, a cpIL-4 protein that can be used in the
fusion proteins
of the present disclosure includes an IL-4 protein in which residues 105-129
of native
human IL-4 (e.g., SEQ ID NO: 1) or an alternative IL-4 sequence (e.g., SEQ ID
NO:2), the
numbering excluding the methionine at the N-terminus, are joined to residues 1-
104 with a
GGNGG linker and an initial methionine residue, as described in, for example,
U.S. Patent
No. 6,011,002, issued January 4, 2000, to Pastan et al.
[0050] Exemplary IL-4 proteins that can be used in the fusion proteins of the
present
disclosure include those described herein, as well as sequences having at
least 80%
sequence identity, at least 85%, at least 90%, at least 95%, at least 98% or
even at least
99% sequence identity to native IL-4 ("variant IL-4 proteins"), as long as the
variant IL-4
protein retains the ability to bind the IL-4 receptor, or retains increased
selectivity for the
7c (Type I receptor) relative to IL-13R al (Type II receptor) or vice versa as
described, for
example, in Junttila etal. (Nature Chemical Biology 8:990-998, 2012), or
retains a desired
biological activity.
100511 It is to be understood that IL-4 proteins according to the present
disclosure include
fragments that can be smaller than the native 129 amino acid IL-4 protein, as
long as the
IL-4 protein fragment retains the ability to bind the IL-4 receptor, or
retains increased
selectivity for the 7c (Type I receptor) relative to IL-13R al (Type II
receptor) or vice
versa as described, for example, in Junttila et al. (Nature Chemical Biology
8:990-998,
2012), or retains a desired biological activity, whether as a fragment of the
native
sequence, or in a cp form or fragment thereof
100521 It is also to be understood that the present disclosure encompasses
nucleic acid
molecules that encode an IL-4 protein as described herein or known in the art,
including
but not limited to RNA sequences corresponding to the DNA sequences described
herein.
100531 Exemplary IL-4 nucleic acid molecules include:
ATGCACAAATGCGACATTACCCTGCAAGAGATCATTAAGACCCTGAACAGCC
TGACCGAGCAAAAGACCCTGTGTACCGAACTGACCGTCACGGACATCTTCGC
9
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
TGCGTCCAAGGACACTACGGAAAAGGAAACGTTCTGICGTGCGGCGACGGT
GCTGCGCCAGTTCTACAGCCACCATGAGAAAGATACCCGTTGCCTCGGIGC
GACCGCGCAACAGTTCCACCGTCACAAACAGCTGATTCGCTICCTGAAGCGT
CIGGATCGCAACCTGIGGGGTTTGGCGGGICTGAACTCCTGICCAGTCAAAG
AAGCCAATCAGTCTACGCTGGAAAACTTTTTGGAGCGTCTGAAAACTATCATG
CGTGAGAAGTACAGCAAATGCAGCAGC (IL4; SEQ ID NO: 30);
ATGGATACCACCGAGAAAGAAACGTICTGCCGTGCTGCCACTGTCCIGCGCC
AGTTITACAGCCATCACGAAAAGGACACCCGTTGCCTGGGTGCGACGGCGC
AGCAATTCCACCGCCACAAACAGCTGATTCGTTTCCTGAAGCGTCTGGACCG
TAACCTGTGGGGTCTGGCGGGICTGAACAGCTGTCCAGTGAAAGAAGCGAA
TCAGAGCACCTTGGAGAATTTCCTCGAACGCCTGAAAACCATCATGCGTGAG
AAATACAGCAAGTGTICTAGCGGCGGTAACGGTGGCCACAAATGCGATATCA
CCCTGCAAGAGATCATTAAGACGCTGAACTCCTTGACGGAACAAAAGACCCT
GTGTACTGAGCTGACGGTCACCGACATTTTCGCGGCGTCC (cpIL4; SEQ ID
NO: 31);
ATGGATACTACCGAGAAAGAAACGTTTIGCCGTGCTGCGACCGTCCTGCGTC
AGTTCTACAGCCACCACGAAAAGGACACCCGCTGICIGGGTGCGACTGCCC
AACAATTCCATCGTCACAAACAGCTGATTCGTTTCCTGAAGCGTCTGGACCG
CAACCTGIGGGGICTGGCGGGCTTGAACTCCTGCCCAGTCAAAGAAGCGAA
CCAAAGCACCCTGGAAAACTICTIGGAGCGTCTGAAAACGATCATGAAAGAG
AAGTTCCGCAAGTGTAGCAGCGGIGGTAATGGTGGCCACAAGTGCGACATTA
CGCTGCAGGAAATCATTAAGACCCTGAACTCTCTGACCGAGCAGAAAACCCT
CIGTACCGAGCTGACGGIGACGGATATCITTGCGGCGAGC (the cpKFR; SEQ
ID NO: 32); and
ATGGATACCACCGAAAAAGAAACTITTTGICGTGCCGCGACTGTCCIGCGCC
AGTTCTACAGCCACCACGAAAAGGACACCCGTTGCCIGGGTGCGACCGCTC
AACAATTCCATCGCCACAAACAGCTGATTCGITTCCTGAAACGTCTGGATCGC
AACCTGTGGGGTCTGGCGGGTTTGAACAGCTGTCCAGTCAAAGAAGCGAAC
CAGAGCACCCTGGAAAACTITCTGGAGCGICTGCGIGTTATCATGCAGAGCA
AGTGGTICAAGTGCGGTGCGGGTGGCAATGGTGGCCACAAGIGTGACATTA
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
CCTTGCAAGAGATTATCAAAACGCTGAACTCTCTGACCGAGCAAAAGACGCT
GTGCACCGAGCTGACGGTGACGGACATCTTCGCGGCGTCC (cpS4; SEQ ID
NO: 33).
[0054] IL-13 proteins or IL-13 "protein moieties" include native IL-13
proteins, as well as
variant IL-13 proteins. A "native" or "wild type" IL-13 sequence, as used
herein, refers to
a human IL-13 sequence, whether purified from natural sources or made using
recombinant techniques, and including the amino acid sequence (with an
additional
methionine at the N-terminus) as follows:
MPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINV
SGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFRE
GQFN (SEQ ID NO: 7).
[0055] In some embodiments, IL-13 proteins that can be used in the fusion
proteins of the
present disclosure are variant IL-13 proteins that have increased selectivity
for IL-13Ra1
(type II receptor) relative wild-type IL-13 protein. For example, the IL-13
variant
sequence may include the amino acid sequence (with an additional methionine at
the N-
terminus) as follows:
MPGPVPPSTAVRELIEELINITQNQKAPLCNGSMVWSINRTAGMYCAALESLINVS
GCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRSSKIEVAQFVKDLLFHLRTLFREG
QFN (the "All" variant; SEQ ID NO: 8).
100561 In some embodiments, a variant IL-13 protein that has increased
selectivity for IL-
13Ra1 (type II receptor) relative wild-type IL-13 protein is an IL-13 protein
that includes
the following mutations relative to the sequence of native human IL-13 (SEQ ID
NO: 7),
the numbering excluding the methionine at the N-terminus:
LlOWE12A/V18I/R65D/D87S/T885/L101F/K104R/K105T (the "DN" variant). For
example, the IL-13 variant sequence may include the amino acid sequence (with
an
additional methionine at the N-terminus) as follows:
MPGPVPPSTAVRALIEELINITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVS
GCSAIEKTQDMLSGFCPHKVSAGQFSSLHVRSSKIEVAQFVKDLLFHLRTLFREG
QFN (SEQ 1D NO: 9).
11
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
[0057] In some embodiments, IL-13 proteins that can be used in the fusion
proteins of the
present disclosure are circularly permuted (cp). In some embodiments, a
variant cpIL-13
protein that can be used in the fusion proteins of the present disclosure
includes an IL-13
protein in which residues 44-114 of native human IL-13 (SEQ ID NO: 7) are
joined to
residues 1-43 with a linker and an initial methionine residue, as follows:
MYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVK
DLLLHLKKLFREGQFNGGSGPGPVPPSTALRELIEELVNITQNQKAPLCNGSMV
WSINLTAG (SEQ ID NO: 10).
[0058] In some embodiments, a variant cpIL-13 protein that can be used in the
fusion
proteins of the present disclosure is as follows:
MYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVK
DLLLHLKKLFREGQFNGGSGMPGPVPPSTALRELIEELVNITQNQKAPLCNGSMV
WSINLTAG (SEQ ID NO: 11).
[0059] In alternative embodiments, a variant cp1L-13 protein that can be used
in the fusion
proteins of the present disclosure includes an IL-13 protein in which residues
44-114 of
native human IL-13 (SEQ ID NO: 7) are joined to residues 1-43 with a linker
and an initial
methionine residue, in the context of the "Al 1" variant, as follows:
MYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRSSKIEVAQFVK
DLLFHLRTLFREGQFNGGSGPGPVPPSTAVRELIEELINITQNQKAPLCNGSMVW
SINRTAG (SEQ ID NO: 12).
[0060] In some embodiments, a variant cpIL-13 protein that can be used in the
fusion
proteins of the present disclosure is as follows:
MYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRSSKIEVAQFVK
DLLFHLRTLFREGQFNGGSGMPGPVPPSTAVRELIEELINITQNQKAPLCNGSMV
WSINRTAG (SEQ ID NO: 13).
[0061] In alternative embodiments, a variant cp1L-13 protein that can be used
in the fusion
proteins of the present disclosure includes an IL-13 protein in which residues
44-114 of
native human IL-13 (SEQ ID NO: 7) are joined to residues 1-43 with a linker
and an initial
methionine residue, in the context of the "DN" variant, as follows:
12
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
MYCAALESLINVSGCSAIEKTQDMLSGFCPHKVSAGQFSSLHVRSSKIEVAQFVK
DLLFHLRTLFREGQFNGGSGPGPVPPSTAVRALIEELINITQNQKAPLCNGSMVW
SINLTAG (SEQ ID NO: 14).
[0062] In some embodiments, a variant cpIL-13 protein that can be used in the
fusion
proteins of the present disclosure is as follows:
MYCAALESLINVSGCSAIEKTQDMLSGFCPHKVSAGQFSSLHVRSSKIEVAQFVK
DLLFHLRTLFREGQFNGGSGMPGPVPPSTAVRALIEELINITQNQMPLCNGSMV
WSINLTAG (SEQ ID NO: 15).
[0063] Exemplary IL-13 proteins that can be used in the fusion proteins of the
present
disclosure include those described herein, as well as sequences having at
least 80%
sequence identity, at least 85%, at least 90%, at least 95%, at least 98% or
even at least
99% sequence identity to native IL-13 ("variant IL-13 proteins"), as long as
the variant IL-
13 protein retains the ability to bind the IL-13 receptor, or retains
increased selectivity for
the IL-13Ra1 (type II receptor) relative to wild-type IL-13 protein, or
retains a desired
biological activity.
[0064] It is to be understood that IL-13 proteins according to the present
disclosure include
fragments that can be smaller than the native 114 amino acid IL-13 protein, as
long as the
IL-13 protein fragment retains the ability to bind the IL-13 receptor, or
retains increased
selectivity for the IL-13Ra1 (type II receptor) relative to wild-type IL-13
protein, or retains
a desired biological activity.
100651 It is also to be understood that the present disclosure encompasses
nucleic acid
molecules (including but not limited to RNA sequences or DNA sequences) that
encode an
IL-13 protein as described herein or known in the art.
[0066] BCL-2 Family Proteins
[0067] Bc1-2-related proteins or polypeptides ("Bc1-2 family proteins" or "Bc1-
2 family
members") are involved in regulation of apoptosis. Bc1-2 family proteins fall
into two
distinct categories: those that inhibit cell death (the "anti-apoptotic" Bc1-2
family proteins)
and those that enhance cell death (the "pro-apoptotic" Bc1-2 family proteins).
Bc1-2 family
proteins share one to four conserved Bc1-2 homology (BH) domains, designated
BH1,
13
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
BH2, BH3, and BH4.
100681 Pro-apoptotic Bc1-2 family proteins include those having a BH3 domain,
such as
Bad (e.g., Accession no: NP116784, CAG46757 or Q92934), Bik/Nbk (e.g.,
Accession no:
CAG30276 or Q13323), Bid (e.g., Accession no: CAG28531 or P55957), Bim/Bod
(e.g.,
Accession no: NP619527), Hrk (Accession no: 000198), Bak, or Bax. In some
embodiments, pro-apoptotic Bc1-2 family proteins that can be used in the
fusion proteins
according to the present disclosure are mutated (for example at serine
residues e.g., serine
to alanine mutations) to prevent phosphorylation.
100691 Bad, Bc1-2-associated agonist of cell death, is a regulator of
programmed cell death
(apoptosis). Bad positively regulates cell apoptosis by forming heterodimers
with Bc1-xt,
and Bc1-2, and reversing their death repressor activity. Pro-apoptotic
activity of Bad is
regulated through its phosphorylation. Exemplary Bad proteins that can be used
in the
fusion proteins of the present disclosure include those in GenBank Accession
Nos.
CAG46757; AAH01901.1; and CAG46733.1, as well as those sequences provided in
U.S.
Pat. No. 6,737,511 (sequences herein incorporated by reference) and described
herein, as
well as sequences having at least 80% sequence identity, at least 85%, at
least 90%, at least
95%, at least 98% or even at least 99% sequence identity to such sequences, as
long as the
variant retains or has enhanced biological activity of the native Bad protein.
In some
embodiments, a Bad protein that can be used in the fusion proteins according
to the present
disclosure contains serine mutations at positions 112 and/or 136 to reduce
phosphorylation.
In some embodiments, a Bad protein that can be used in the fusion proteins
according to
the present disclosure contains serine to alanine mutations at positions 112
and/or 136 to
reduce phosphorylation. In some embodiments, a Bad protein that can be used in
the fusion
proteins according to the present disclosure includes a sequence as follows,
or fragment
thereof:
FQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDASHQQE
QPTSSSHHGGAGAVEIRSRHSSYPAGTEDDEGIVIGEEPSPFRGRSRAAPPNLW
AAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSVVTRVFQSVWVD
RNLGRGSSAPSQ (SEQ ID NO: 16);
FQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDASHQQE
14
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
QPTSSSHHGGAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGRSRSAPPNLW
AAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSWIRVFQSWVVD
RNLGRGSSAPSQ (Accession no: NP116784; SEQ ID NO: 18); or
FQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDASHQQE
QPTSSSHHGGAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGRSRSAPPNLW
AAQRYGRELRRMSDEFVDSFKKGLP RPKSAGTATQ MRQSSSWERV
FQSVVVVDRNLGRGSSAPSQ (Accession no: CAG46757;SEQ ID NO: 19).
100701 In some embodiments, a Bad protein that can be used in the fusion
proteins
according to the present disclosure includes a variant sequence as follows, or
fragment
thereof:
FQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDASHQQE
QPTSSSHHGGAGAVEIRSRHSAYPAGTEDDEGMGEEPSPFRGRSRAAPPNLW
AAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSWTRVFQSVVVVD
RNLGRGSSAPSQ (SEQ ID NO: 17).
100711 An exemplary BildNbk protein molecule that can be used in the fusion
proteins
according to the present disclosure includes a sequence as follows, or
fragment thereof:
SEVRPLSRDILIVIETLLYEQLLEPPTMEVLGMTDSEEDLDPIVIEDFDSLECMEGSD
ALALRLACIGDEMDVSLRAPRLAQLSEVAMHSLGLAFIYDQTEDIRDVLRSFMDG
FTTLKENIIVIRFWRSPNPGS\ANSCEQVLLALLLLLALLLPLLSGGLHLLLK
(Accession no: CAG30276; SEQ ID NO: 20).
100721 An exemplary Bid protein molecule that can be used in the fusion
proteins
according to the present disclosure includes a sequence as follows, or
fragment thereof:
DCEVNNGSSLRDECITNLLVFGFLQSCSDNSFRRELDALGHELPVLAPQWEGYD
ELQTDGNRSSHSRLGRIEADSESQEDIIRNIARHLAQVGDSMDRSIPPGLVNGLA
LQLRNTSRSEEDRNRDLATALEQLLQAYPRDMEKEKTMLVLALLLAKKVASHTPS
LLRDVFHTTVNFINQNLRTYVRSLARNGIVID (Accession no: CAG28531; SEQ ID
NO: 21).
100731 An exemplary Bim/Bod protein molecule that can be used in the fusion
proteins
according to the present disclosure includes a sequence as follows:
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
AKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSLQTEPQGNPEGNHGGEGD
SCPHGSPQGPLAPPASPGPFATRSPLFIFMRRSSLLSRSSSGYFSFDTDRSPAP
MSCDKSTQTPSPPCQAFNHYLSAMASMRQAEPADMRPEIWIAQELRRIGDEFNA
YYARRVFLNNYQAAEDHPRMVILRLLRYIVRLVWRMH (Accession no: MP619527;
SEQ ID NO: 22).
[0074] An exemplary Hrk protein molecule that can be used in the fusion
proteins
according to the present disclosure includes a sequence as follows:
CPCPLHRGRGPPAVCACSAGRLGLRSSAAQLTAARLKALGDELHQRTMWRRRA
RSRRAPAPGALPTYWPVVLCAAAQVAALAAVVLLGRRN (Accession no: 000198;
SEQ ID NO: 23).
100751 In some embodiments, a pro-apoptotic Bc1-2 family protein includes at
least a
fragment of a Bc1-2 family member, where the pro-apoptotic Bc1-2 family
protein or
fragment is capable of inhibiting cell survival, inhibiting cell
proliferation, or enhancing
cell death or apoptosis. By "inhibiting cell survival" is meant decreasing
(e.g., by at least
10%, 20%, 30%, or by as much as 50%, 75%, 85% or 90% or more) the probability
that a
cell at risk of cell death will survive. By "inhibiting cell proliferation" is
meant
decreasing (e.g., by at least 10%, 20%, 30%, or by as much as 50%, 75%, 85% or
90% or
more) the growth or proliferation of a cell. By "enhancing cell death or
apoptosis" is meant
increasing (e.g., by at least 10%, 20%, 30%, or by as much as 50%, 75%, 85% or
90% or
more) the probability that a cell at risk of cell death will undergo
apoptotic, necrotic, or any
other form of cell death. Suitable assays for measuring the inhibition of cell
survival,
inhibition of cell proliferation, or enhancement of cell death or apoptosis
are described
herein or known in the art.
[0076] It is also to be understood that the present disclosure encompasses
nucleic acid
molecules (e.g., RNA sequences or DNA sequences) that encode a pro-apoptotic
Bc1-2
family member as described herein, including but not limited to RNA sequences
corresponding to the DNA sequences described herein.
[0077] An exemplary pro-apoptotic Bc1-2 family member nucleic acid molecule
includes:
GGTAGCTTTCAGATCCCGGAATTTGAGCCGAGCGAGCAAGAGGATTCAAGCA
GCGCGGAGCGCGGTCTGGGTCCGAGCCCGGCAGGCGACGGTCCGAGCGG
16
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
CAGCGGCAAGCATCACCGCCAGGCGCCAGGCCTGCTGTGGGATGCATCGCA
TCAACAGGAACAACCGACGAGCAGCAGCCATCATGGIGGCGCTGGTGCGGT
TGAGATTAGATCGCGCCACTCCGCATATCCTGCCGGCACCGAAGATGACGAA
GGCATGGGCGAGGAACCGAGCCCGTTCCGTGGCCGTAGCCGTGCTGCACC
GCCGAATCTGIGGGCCGCACAGCGTTATGGICGCGAGTTGCGTCGCATGTC
CGACGAGITTGTTGACTCCTICAAGAAAGGTTTACCGCGTCCGAAATCTGCC
GGTACCGCGACGCAGATGCGTCAGAGCAGCAGCTGGACCCGCGTGTTTCAA
TCTTGGTGGGATCGTAATCTGGGTCGTGGTAGCAGCGCACCGAGC CAA
(variant BAD; SEQ ID NO: 34).
100781 IL-4 Receptor Binding Protein-Bc1-2 Family Fusion Proteins
[0079] "Fusion proteins" according to the present disclosure include IL-4R
bindingproteins, such as IL-4 and IL-13, joined to a pro-apoptotic Bc1-2
family member,
with optional additional sequences or moieties (such as linkers), as described
herein, as
well as nucleic acid molecules encoding such fusion proteins. Also encompassed
are
recombinant nucleic acid molecules in which a nucleic acid sequence encoding a
fusion
protein is operably linked to a promoter, vectors containing such a molecule,
and
transgenic cells comprising such a molecule.
100801 IL-4 (including cpIL-4 and IL-4 fragments and variants) can be linked
to pro-
apoptotic Bc1-2 family polypeptides comprising a BH3 domain as exemplified by
Bad,
Bik/Nbk, Bid, Bim/Bod, Hrk, Bak, or Bax or combinations thereof, or fragments
or
variants thereof, as long as pro-apoptotic activity is retained. Any form or
derivative of IL-
4 can be used. For example, IL-4 or fragments of IL-4 that bind to the IL-4
receptor can be
used. Additionally, multiple pro-apoptotic Bc1-2 family proteins or fragments
or variants
thereof can be joined to IL-4 or fragments or variants thereof or multiple IL-
4 proteins or
fragments or variants thereof can be joined to pro-apoptotic Bc1-2 family
proteins or
fragments or variants thereof.
100811 IL-13 (including IL-13 fragments or variants) can be linked to pro-
apoptotic Bc1-2
family polypeptides, for example those comprising a BH3 domain, as exemplified
by Bad,
Bik/Nbk, Bid, Bim/Bod, or Hrk, or combinations thereof, as long as the
combination or
fragments or variants thereof retains pro-apoptotic activity. Any form or
derivative of IL-
17
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
13 can be used. For example, IL-13 or fragments of IL-13 that bind to the IL-
13 receptor
can be used. Additionally, multiple pro-apoptotic Bc1-2 family proteins or
fragments or
variants thereof can be joined to IL-13 or fragments or variants thereof or
multiple IL-13
proteins or fragments or variants thereof can be joined to pro-apoptotic Bc1-2
family
proteins or fragments or variants thereof.
100821 A cpIL-4, can be linked to pro-apoptotic Bc1-2 family polypeptides,
such as those
comprising a BH3 domain as exemplified by Bad, Bildl\lbk, Bid, Bim/Bod, Hrk,
Bak, or
Bax or combinations thereof, or fragments or variants thereof, as long as pro-
apoptotic
activity is retained. Any form or derivative of cpIL-4 can be used.
Additionally, multiple
cpIL-4 proteins or fragments or variants thereof, can be joined to a pro-
apoptotic Bc1-2
family protein or fragments or variants thereof, or multiple pro-apoptotic Bc1-
2 family
proteins or fragments or variants thereof, can be joined to cpIL-4 proteins or
fragments or
variants thereof,.
100831 Exemplary fusion proteins are listed in Table 1.
Table 1, IL-4/Bel-2 Family Fusion Proteins
Name Circularly permuted Linker BcI-2 Family Description
IL-4 Protein
1L4- MHKCDITLQEI1KTLN GS FQIPEFEPSEQED Human IL-4 fused
Bad SLTEQKTLCTELTVT SSSAERGLGPSP to human Bad
DIFAASKDTTEKETF AGDGPSGSGKHH variant via a GS
CRAATVLRQFYSHH RQAPGLLWDASH linker
EKDTRCLGATAQQF QQEQPTSSSHHG
HRHKQURFLKRLDR GAGAVEIRSRHSA
NLWGLAGLNSCPVK YPAGTEDDEGMG
EANQSTLENFLERLK EEPSPFRGRSRA
TIMREKYSKCSS APPNLWAAQRYG
(SEQ ID NO: 2). RELRRMSDEFVD
SFKKGLPRPKSAG
TATQMRQSSSWT
RVFQSVVWDRNL
GRGSSAPSQ
(SEQ ID NO: 17).
Fusion Amino Acid Sequence:
MHKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKDTTEKETFCRAATVLRQFYSHHEK
DTRCLGATAQQFHRHKQURFLKRLDRNLWGLAGLNSCPVKEANQSTLENFLERLKTIM
REKYSKCSSFQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLVVDASH
QQEQPISSSHHGGAGAVEIRSRHSAYPAGTEDDEGMGEEPSPFRGRSRAAPPNLWAA
QRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSVVTRVFQSVVVVDRNLGRGS
SAPSQ (SEQ ID NO: 24).
18
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
Fusion DNA Sequence:
ATGCACAAATGCGACATTACCCTGCAAGAGATCATTAAGACCCTGAACAGCCTGACC
GAGCAAAAGACCCTGIGTACCGAACTGACCGTCACGGACATCTTCGCTGCGTCCAA
GGACACTACGGAAAAGGAAACGTTCTGTCGTGCGGCGACGGTGCTGCGCCAGTTCT
ACAGCCACCATGAGAAAGATACCCGTTGCCTCGGTGCGACCGCGCAACAGTTCCAC
CGTCACAAACAGCTGATTCGCTTCCTGAAGCGICTGGATCGCAACCTGIGGGGITTG
GCGGGTCTGAACTCCTGTCCAGTCAAAGAAGCCAATCAGTCTACGCTGGAAAACTTT
TTGGAGCGICTGAAAACTATCATGCGTGAGAAGTACAGCAAATGCAGCAGCGGTAG
CTTTCAGATCCCGGAATTTGAGCCGAGCGAGCAAGAGGATTCAAGCAGCGCGGAGC
GCGGTCTGGGTCCGAGCCCGGCAGGCGACGGTCCGAGCGGCAGCGGCAAGCATC
ACCGCCAGGCGCCAGGCCTGCTGTGGGATGCATCGCATCAACAGGAACAACCGAC
GAGCAGCAGCCATCATGGTGGCGCTGGTGCGGTTGAGATTAGATCGCGCCACTCCG
CATATCCTGCCGGCACCGAAGATGACGAAGGCATGGGCGAGGAACCGAGCCCGTT
CCGIGGCCGTAGCCGIGCTGCACCGCCGAATCTGTGGGCCGCACAGCGTTATGGT
CGCGAGTTGCGTCGCATGTCCGACGAGTTTGTTGACTCCTTCAAGAAAGGTTTACCG
CGTCCGAAATCTGCCGGTACCGCGACGCAGATGCGTCAGAGCAGCAGCTGGACCC
GCGTGTTTCAATCTTGGTGGGATCGTAATCTGGGTCGTGGTAGCAGCGCACCGAGC
CAA (SEQ ID NO: 35).
cpIL4- MDTTEKETFCRAATV GS FQIPEFEPSEQED Circularly
Bad LRQFYSH H EKDTRC SSSAERGLGPSP permuted human
LGATAQQFH RHKQLI AGDGPSGSGKHH IL-4 fused to
RFLKRLDRN LWG LA RQAPGLLWDASH human Bad
GLNSCPVKEANQST QQEQPTSSSHHG variant
LEN FLERLKTIM REK GAGAVEIRSRHSA via a GS linker
YSKCSSGGNGGH KC YPAGTEDDEGMG
DITLQEI IKTLNSLTEQ EEPSPFRGRSRA
KTLCTE LTVTD I FAAS APPN LWAAQ RYG
(SEQ ID NO: 3). RELRRMSDEFVD
SFKKGLPRPKSAG
TATQM RQSSSVVT
RVFQSVVWDRNL
GRGSSAPSQ
(SEQ ID NO: 17).
Fusion Amino Acid Sequence:
MDTTEKETFCRAATVLRQFYSH H EKDTRCLGATAQQF H RH KQLI RFLKRLDR N LWG LAG
LNSCPVKEANQSTLEN FLERLKTI M REKYSKCSSGGNGGHKCDITLQEI I KTLNSLTEQKT
LCTELTVTDI FAASGSFQI PEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKH H RQAPGL
LWDASHQQEQPTSSSHHGGAGAVEI RSRHSAYPAGTEDDEGMGEEPSPFRGRSRAAP
PN LWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQM RQSSSVVTRVFQSWVVDR
NLGRGSSAPSQ (SEQ ID NO: 25).
Fusion DNA Sequence:
ATGGATACCACCGAGAAAGAAACGTICTGCCGTGCTGCCACTGTCCTGCGCCAGITT
TACAGCCATCACGAAAAGGACACCCGTTGCCTGGGTGCGACGGCGCAGCAATTCCA
CCGCCACAAACAGCTGATTCGTTTCCTGAAGCGTCTGGACCGTAACCTGTGGGGTCT
GGCGGGICTGAACAGCTGICCAGTGAAAGAAGCGAATCAGAGCACCTTGGAGAATT
TCCTCGAACGCCTGAAAACCATCATGCGTGAGAAATACAGCAAGTGTTCTAGCGGCG
GTAACGGIGGCCACAAATGCGATATCACCCTGCAAGAGATCATTAAGACGCTGAACT
19
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
CCTTGACGGAACAAAAGACCCTGTGTACTGAGCTGACGGTCACCGACATTTTCGCGG
CGTCCGGTAGCTTTCAGATCCCGGAATTTGAGCCGAGCGAGCAAGAGGATTCAAGC
AGCGCGGAGCGCGGTCTGGGTCCGAGCCCGGCAGGCGACGGTCCGAGCGGCAGC
GGCAAGCATCACCGCCAGGCGCCAGGCCTGCTGTGGGATGCATCGCATCAACAGG
AACAACCGACGAGCAGCAGCCATCATGGTGGCGCTGGTGCGGTTGAGATTAGATCG
CGCCACTCCGCATATCCTGCCGGCACCGAAGATGACGAAGGCATGGGCGAGGAAC
CGAGCCCGTTCCGTGGCCGTAGCCGTGCTGCACCGCCGAATCTGTGGGCCGCACA
GCGTTATGGTCGCGAGTTGCGTCGCATGTCCGACGAGTTTGTTGACTCCTTCAAGAA
AGGITTACCGCGTCCGAAATCTGCCGGTACCGCGACGCAGATGCGTCAGAGCAGCA
GCTGGACCCGCGTGTTTCAATCTTGGTGGGATCGTAATCTGGGTCGTGGTAGCAGC
GCACCGAGCCAA (SEQ ID NO: 36).
cpKFR4- MDTTEKETFCRAATV GS FQIPEFEPSEQEDS Circularly
Bad LRQFYSH H EKDTRCL SSAERGLGPSPAG permuted KFR
GATAQQFHRHKQLIR DGPSGSGKH H RQ variant of
FLKRLDRNLWGLAGL APGLLWDASHQQE human IL-4
NSCPVKEANQSTLEN QPTSSSHHGGAGA fused to human
F LER LKTI MKEKFRKC VEIRSRHSAYPAG Bad variant via
SSGGNGGHKCDITLQ TEDDEGMGEEPSP a GS linker
El I KTLNSLTEQKTLCT FRGRSRAA PP N LW
ELTVTDIFAAS (SEQ AAQRYGRELRRMS
ID NO: 5), DEFVDSFKKGLPR
PKSAGTATQM RQS
SSVVTRVFQSVVVVD
RN LGRGSSAPSQ
(SEQ ID NO: 17).
Fusion Amino Acid Sequence:
MDTTEKETFCRAATVLRQFYSH H EKDTRCLGATAQQF H RH KQ LI RF LKRLDRN LWG LAG
LNSCPVKEANQSTLEN F LER LKTI M KEKF RKCSSGGNGGH KCDITLQ El I KTLNSLTEQKT
LCTELTVTDI FAASGSFQI P EF EPSEQ EDSSSA ERG LG PSPAG DGPSGSG KH H RQAPGL
LWDASHQQEQPTSSSHHGGAGAVEI RSR HSAYPAGTEDDEGMGEEPSPFRGRSRAAP
PN LWAAQRYGRELR RMSDEFVDSFKKGLPRPKSAGTATQM RQSSSVVTRVFQSVVVVDR
NLGRGSSAPSQ (SEQ ID NO: 26).
Fusion DNA Sequence:
ATGGATACTACCGAGAAAGAAACGTTTTGCCGTGCTGCGACCGTCCTGCGTCAGTTC
TACAGCCACCACGAAAAGGACACCCGCTGICTGGGIGCGACTGCCCAACAATTCCA
TCGTCACAAACAGCTGATTCGTTTCCTGAAGCGTCTGGACCGCAACCTGTGGGGTCT
GGCGGGCTTGAACTCCTGCCCAGICAAAGAAGCGAACCAAAGCACCCTGGAAAACT
TCTIGGAGCGICTGAAAACGATCATGAAAGAGAAGTTCCGCAAGTGTAGCAGCGGTG
GTAATGGTGGCCACAAGTGCGACATTACGCTGCAGGAAATCATTAAGACCCTGAACT
CTCTGACCGAGCAGAAAACCCTCTGTACCGAGCTGACGGTGACGGATATCITTGCG
GCGAGCGGTAGCTTTCAGATCCCGGAATTTGAGCCGAGCGAGCAAGAGGATTCAAG
CAGCGCGGAGCGCGGTCTGGGTCCGAGCCCGGCAGGCGACGGTCCGAGCGGCAG
CGGCAAGCATCACCGCCAGGCGCCAGGCCTGCTGTGGGATGCATCGCATCAACAG
GAACAACCGACGAGCAGCAGCCATCATGGTGGCGCTGGTGCGGTTGAGATTAGATC
GCGCCACTCCGCATATCCTGCCGGCACCGAAGATGACGAAGGCATGGGCGAGGAA
CCGAGCCCGTTCCGTGGCCGTAGCCGTGCTGCACCGCCGAATCTGTGGGCCGCAC
AGCGTTATGGTCGCGAGTTGCGTCGCATGTCCGACGAGTTTGTTGACTCCTTCAAGA
AAGGTTTACCGCGTCCGAAATCTGCCGGTACCGCGACGCAGATGCGTCAGAGCAGC
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
AGCTGGACCCGCGTGTTTCAATCTTGGTGGGATCGTAATCTGGGTCGTGGTAGCAG
CGCACCGAGCCAA (SEQ ID NO: 37).
cpS4- MDTTEKETFCRAATV GS FQIPEFEPSEQE Circularly permuted
Bad LRQFYSH H EKDTRCL DSSSAERGLGPS RCA (Super-4)
GATAQQFH RH KQLI R PAGDGPSGSGK variant of IL-4 fused
FLKRLDRN LWGLAGL HH RQAPGLLVVD to pro-apoptotic
NSCPVKEANQSTLEN ASHQQEQPTSSS human Bad with
FLERLRVIMKWFK HHGGAGAVEI RS GS linker;
CGAGGNGGH KCDITL RHSAYPAGTEDD Mutations in 575A
QEI IKTLNSLTEQKTL EGMGEEPSPFR and 599A of Bad
CTELTVTD I FAAS GRSRAAPPN LW
(SEQ ID NO: 4). AAQRYGRELRR
MSDEFVDSFKKG
LPRPKSAGTATQ
M RQSSSWTRVF
QSVVWDRN LGRG
SSAPSQ (SEQ ID
NO: 17).
Fusion Amino Acid Sequence:
MDTTEKETFCRAATVLRQFYSH H EKDTRCLGATAQQF H RH KQLI R FLKRLDRN LWG LAG
LNSCPVKEANQSTLEN FLERLRVI MaaKWFKCGAGGNGGH KCDITLQEI I KTLNSLTEQK
TLCTELTVTDI FAASGSFQI PEF EPSEQEDSSSAERGLGPSPAGDGPSGSGKHH RQAPG
LLVVDASHQQEQPTSSSH HGGAGAVEI RSRHSAYPAGTEDDEGMGEEPSPFRGRSRAA
PPN LWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQM RQSSSWTRVFQSVWVD
RNLGRGSSAPSQ (SEQ ID NO: 27).
Fusion DNA Sequence:
ATGGATACCACCGAAAAAGAAACTTTTTGTCGTGCCGCGACTGTCCTGCGCCAGTTC
TACAGCCACCACGAAAAGGACACCCGTTGCCTGGGTGCGACCGCTCAACAATTCCA
TCGCCACAAACAGCTGATTCGTTTCCTGAAACGTCTGGATCGCAACCTGTGGGGTCT
GGCGGGITTGAACAGCTGTCCAGTCAAAGAAGCGAACCAGAGCACCCTGGAAAACT
TTCTGGAGCGTCTGCGTGTTATCATGCAGAGCAAGTGGTTCAAGTGCGGTGCGGGT
GGCAATGGTGGCCACAAGIGTGACATTACCTTGCAAGAGATTATCAAAACGCTGAAC
TCTCTGACCGAGCAAAAGACGCTGTGCACCGAGCTGACGGTGACGGACATCTTCGC
GGCGTCCGGTAGCTTTCAGATCCCGGAATTTGAGCCGAGCGAGCAAGAGGATTCAA
GCAGCGCGGAGCGCGGICTGGGTCCGAGCCCGGCAGGCGACGGICCGAGCGGCA
GCGGCAAGCATCACCGCCAGGCGCCAGGCCTGCTGTGGGATGCATCGCATCAACA
GGAACAACCGACGAGCAGCAGCCATCATGGTGGCGCTGGTGCGGTTGAGATTAGAT
CGCGCCACTCCGCATATCCTGCCGGCACCGAAGATGACGAAGGCATGGGCGAGGA
ACCGAGCCCGTTCCGTGGCCGTAGCCGTGCTGCACCGCCGAATCTGIGGGCCGCA
CAGCGTTATGGICGCGAGTTGCGTCGCATGTCCGACGAGTTIGTTGACTCCTTCAAG
AAAGGTTTACCGCGTCCGAAATCTGCCGGTACCGCGACGCAGATGCGTCAGAGCAG
CAGCTGGACCCGCGTGITTCAATCTIGGIGGGATCGTAATCTGGGTCGTGGTAGCA
GCGCACCGAGCCAA (SEQ ID NO: 38).
100841 The joining or "fusion" of an IL-4R binding protein, such as IL-4 or IL-
13, to a
pro-apoptotic Bc1-2 family member may be direct, such that one portion of the
IL-4R
21
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
binding protein is directly attached to a portion of the pro-apoptotic Bc1-2
family member.
For example, one end of the amino acid sequence of an IL-4R binding protein
can be
directly attached to an end of the amino acid sequence of the pro-apoptotic
Bc1-2 family
member. For example, the C-terminus of the IL-4R binding protein can be linked
to the N-
terminus of the pro-apoptotic Bc1-2 family member, or the C-terminus of the
pro-apoptotic
Bc1-2 family member can be linked to the N-terminus of the IL-4R binding
protein.
Methods of generating such fusion proteins are routine in the art, for example
using
recombinant molecular biology methods.
[0085] Linkers
[0086] In some embodiments, an IL-4R binding protein moiety can be linked to
the pro-
apoptotic Bc1-2 family member moiety indirectly through a linker. The linker
can serve,
for example, simply as a convenient way to link the two moieties, as a means
to spatially
separate the two moieties, to provide an additional functionality to the IL-4R
binding
protein or the pro-apoptotic Bc1-2 family member, or a combination thereof.
[0087] In general, the linker joining the IL-4R binding protein moiety and the
pro-
apoptotic Bc1-2 family member moiety can be designed to (1) allow the two
molecules to
fold and act independently of each other, (2) not have a propensity for
developing an
ordered secondary structure which could interfere with the functional domains
of the two
moieties, (3) have minimal hydrophobic or charged characteristics which could
interact
with the functional protein domains and/or (4) provide steric separation of
the two regions.
For example, in some instances, it may be desirable to spatially separate the
IL-4R binding
protein and the pro-apoptotic Bc1-2 family member to prevent the IL-4R binding
protein
from interfering with the activity of the pro-apoptotic Bc1-2 family member
and/or the pro-
apoptotic Bc1-2 family member interfering with the activity of the IL-4R
binding protein.
The linker can also be used to provide, for example, lability to the
connection between the
IL-4R binding protein and the pro-apoptotic Bc1-2 family member, an enzyme
cleavage
site (for example, a cleavage site for a protease), a stability sequence, a
molecular tag, a
detectable label, or various combinations thereof. In some embodiments, a
linker can be
present between two domains of an IL-4R binding protein (such as in a cp
molecule) or
pro-apoptotic Bc1-2 family member.
22
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
[0088] The linker can be bifunctional or polyfunctional, i.e., contain at
least about a first
reactive functionality at, or proximal to, a first end of the linker that is
capable of bonding
to, or being modified to bond to, the IL-4R binding protein and a second
reactive
functionality at, or proximal to, the opposite end of the linker that is
capable of bonding to,
or being modified to bond to, the pro-apoptotic BcI-2 family member being
modified. The
two or more reactive functionalities can be the same (i.e. the linker is
homobifunctional) or
they can be different (i.e. the linker is heterobifunctional).
[0089] The length and composition of a linker can be varied considerably. The
length and
composition of the linker are generally selected taking into consideration the
intended
function of the linker, and optionally other factors such as ease of
synthesis, stability,
resistance to certain chemical and/or temperature parameters, and
biocompatibility. For
example, the linker should not significantly interfere with the activity of
the IL-4R binding
protein and/or pro-apoptotic Bc1-2 family member.
100901 Linkers suitable for use in a fusion protein according to the present
disclosure
include peptides. The linker can be attached to the IL-4R binding moiety
and/or the pro-
apoptotic Bc1-2 family member moiety using recombinant DNA technology. Such
methods
are well-known in the art and details of this technology can be found, for
example, in
Sambrook, et al. Molecular Cloning: A Laboratory Manual. 2nd ed., Cold Spring
Harbor
Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.,
1989 or
Ausubel et al. Current Protocols in Molecular Biology, John Wiley & Sons,
1994) or
updates thereto.
[0091] The linker peptides can have a chain length of 1 to 500 amino acid
residues (such
as 1 to 100, 1 to 50, 6 to 30, 1 to 40, 1 to 20, or less than 30 amino acids
or 5 to 10 amino
acids). In some embodiments, a linker can be 2, 3, 4, 5, 6, 7, or 8 amino
acids in length, or
can be about 10, 20, 30, 40 or 50 amino acids in length.
[0092] Typically, surface amino acids in flexible protein regions include Gly,
Asn and Ser,
and such amino acids can be used in linker sequences. Other neutral amino
acids, such as
Thr and Ala, can also be used in the linker sequence. Additional amino acids
can be
included in the linker to provide unique restriction sites in the linker
sequence to facilitate
construction of the fusions. In some embodiments, a linker may for instance
include the
23
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
amino acid sequence Gly-Ser (GS) or may be the amino acid sequence Gly-Ser
(GS) or
may include a ubiquitin sequence:
GGGSMQIFVRTLTGRTITLEVEPSDTIENVRARIQDREGIPPDQQRLIFAGRQLEDGRTLS
DYNIQRESTLHLVLRLRGGGS (SEQ ID NO: 28) or variant thereof. Ubiquitin molecules
suitable for use as linkers are described in, for example, Bachran, C. et al.
"Anthrax toxin-
mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the
cytosol of
tumor cells via cleavable ubiquitin fusions MBio. 2013 Apr 30;4(3):e00201-13,
or in PCT
publication WO/2012/139112.
[0093] Peptide linkers that are susceptible to cleavage by enzymes of the
complement
system, urokinase, tissue plasminogen activator, trypsin, plasmin, or another
enzyme
having proteolytic activity may be used in one example. According to another
example, the
IL-4R binding protein can be attached via a linker susceptible to cleavage by
enzymes
having a proteolytic activity such as a urokinase, a tissue plasminogen
activator, plasmin,
thrombin or trypsin. In addition, the IL-4R binding protein can be attached to
the pro-
apoptotic Bc1-2 family member via disulfide bonds (for example, the disulfide
bonds on a
cysteine molecule). For example, in the context of pro-apoptotic Bc1-2 family
proteins,
since many tumors naturally release high levels of glutathione (a reducing
agent) this can
reduce the disulfide bonds with subsequent release of the pro-apoptotic Bc1-2
family
member at the site of delivery.
[0094] In some embodiments, a fusion protein according to the present
disclosure may
include a pro-apoptotic Bc1-2 family member and an IL-4R binding protein
linked by a
cleavable linker region. In another embodiment, the cleavable linker region
can be a
protease-cleavable linker, although other linkers, cleavable for example by
small
molecules, may be used. Examples of protease cleavage sites include those
cleaved by
factor Xa, thrombin and collagenase. In one example, the protease cleavage
site include
those cleaved by a protease that is associated with a disease. In another
example, the
protease cleavage site is one that is cleaved by a protease that is up-
regulated or associated
with cancers in general. Examples of such proteases are uPA, the matrix
metalloproteinase
(MMP) family, the caspases, elastase, prostate specific antigen (PSA, a serine
protease),
and the plasminogen activator family, as well as fibroblast activation
protein. In still
another example, the cleavage site is cleaved by a protease secreted by cancer-
associated
24
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
cells. Examples of these proteases include matrixmetalloproteases, elastase,
plasmin,
thrombin, and uPA. In another example, the protease cleavage site is one that
is up-
regulated or associated with a specific cancer. The precise sequences are
available in the
art and the skilled person will have no difficulty in selecting a suitable
cleavage site. By
way of example, the protease cleavage region targeted by Factor Xa is IEGR.
The protease
cleavage region targeted by enterokinase is DDDDK. The protease cleavage
region
targeted by thrombin is LVPRG. In one example, the cleavable linker region is
one which
is targeted by endocellular proteases.
[0095] The linker can be attached to the IL-4R binding protein moiety and/or
pro-
apoptotic Bc1-2 family member moiety using routine techniques as known in the
art.
[0096] Preparation of IL-4R Binding Protein/Pro-apoptotic BcI-2 Family Fusion
Proteins
[0097] Fusion proteins can be prepared using routine methods as known in the
art. Fusion
proteins, as well as modifications thereto, can be made, for example, by
engineering the
nucleic acid encoding the fusion protein using recombinant DNA technology or
by peptide
synthesis. Modifications to the fusion protein may be made, for example, by
modifying the
fusion protein polypeptide itself, using chemical modifications and/or limited
proteolysis.
Combinations of these methods may also be used to prepare the fusion proteins.
[0098] Methods of cloning and expressing proteins are well-known in the art,
detailed
descriptions of techniques and systems for the expression of recombinant
proteins can be
found, for example, in Current Protocols in Protein Science (Coligan, J. E.,
etal., Wiley &
Sons, New York). Those skilled in the art will understand that a wide variety
of expression
systems can be used to provide the recombinant protein. Accordingly, the
fusion proteins
can be produced in a prokaryotic host (e.g., E. coil, A. salmonicida or B.
subtilis) or in a
eukaryotic host (e.g., Saccharomyces or Pichia; mammalian cells, e.g., COS,
NIH 3T3,
CHO, BHK, 293, or HeLa cells; or insect cells (baculovirus)). The fusion
proteins can be
purified from the host cells using standard techniques known in the art.
[0099] Sequences for various exemplary fusion proteins are provided in Table
1. Variants
and homologs of these sequences can be cloned, if an alternative sequence is
desired, using
standard techniques (see, for example, Ausubel et al., Current Protocols in
Molecular
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
Biology, Wiley & Sons, NY (1997 and updates); Sambrook etal., Sambrook, et al.
Molecular Cloning: A Laboratory Manual. 2nd ed., Cold Spring Harbor
Laboratory, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989 or updates
thereto). For
example, the nucleic acid sequence can be obtained directly from a suitable
organism, such
as Aeromonas hydrophila, by extracting mRNA and then synthesizing cDNA from
the
mRNA template (for example by RT-PCR) or by PCR-amplifying the gene from
genomic
DNA. Alternatively, the nucleic acid sequence encoding either the IL-4R
binding moiety
or the pro-apoptotic Bc1-2 family moiety can be obtained from an appropriate
cDNA
library by standard procedures. The isolated cDNA is then inserted into a
suitable vector,
such as a cloning vector or an expression vector.
[00100] Mutations (if desired) can be introduced at specific, pre-selected
locations
by in vitro site-directed mutagenesis techniques well-known in the art.
Mutations can be
introduced by deletion, insertion, substitution, inversion, or a combination
thereof, of one
or more of the appropriate nucleotides making up the coding sequence.
[00101] The expression vector can further include regulatory elements,
such as
transcriptional elements, required for efficient transcription of the fusion
protein-encoding
sequences. Examples of regulatory elements that can be incorporated into the
vector
include, but are not limited to, promoters, enhancers, terminators, and
polyadenylation
signals. Vectors that include a regulatory element operatively linked to a
nucleic acid
sequence encoding a genetically engineered fusion protein can be used to
produce the
fusion protein.
[00102] The expression vector may additionally contain heterologous
nucleic acid
sequences that facilitate the purification of the expressed fusion protein,
such as affinity
tags such (e.g., metal-affinity tags, histidine tags, avidin/streptavidin
encoding sequences,
glutathione-S-transferase (GST) encoding sequences, maltose binding protein
(MBP)
encoding sequences or biotin encoding sequences). In one example, such tags
are attached
to the N- or C-terminus of a fusion protein, or can be located within the
fusion protein. The
tags can be removed from the expressed fusion protein prior to use according
to methods
known in the art. Alternatively, the tags can be retained on the fusion
protein, providing
that they do not interfere with the ability of the desired activity of the
fusion protein.
26
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
[00103] The fusion protein can include one or more linkers, as well as
other
moieties, as desired and/or as discussed herein. These can include a binding
region, such as
avidin or an epitope, or a tag such as a polyhistidine tag, which can be
useful for
purification and processing of the fusion protein, as well as other linkers as
described
herein. In addition, detectable markers can be attached to the fusion protein,
so that the
traffic of the fusion protein through a body or cell can be monitored
conveniently. Such
markers include radionuclides, enzymes, fluorophores, chromophores, and the
like.
[00104] One of ordinary skill in the art will appreciate that the DNA can
be altered
in numerous ways without affecting the biological activity of the encoded
protein. For
example, PCR can be used to produce variations in the DNA sequence which
encodes a
fusion protein. Such variations in the DNA sequence encoding a fusion protein
can be used
to optimize for codon preference in a host cell used to express the protein,
or may contain
other sequence changes that facilitate expression.
[00105] A covalent linkage of an IL-4R binding protein directly to a pro-
apoptotic
Bc1-2 family member or via a linker may take various forms as is known in the
art. For
example, the covalent linkage may be in the form of a disulfide bond. The DNA
encoding
one of the components can be engineered to contain a unique cysteine codon.
The second
component can be derivatized with a sulfhydryl group reactive with the
cysteine of the first
component. Alternatively, a sulfhydryl group, either by itself or as part of a
cysteine
residue, can be introduced using solid phase polypeptide techniques. For
example, the
introduction of sulfhydryl groups into peptides is described by Hi skey
(Peptides 3:137,
1981).
[00106] Assays
[00107] Fusion proteins can be assayed using standard techniques known in
the art
or described herein.
[00108] For example, the ability of the fusion proteins to kill or inhibit
growth of
cells can be assayed in vitro using suitable cells, typically a cell line
expressing the target
or a cancer cell. In general, cells of the selected test cell line are grown
to an appropriate
density and the candidate fusion protein is added. The fusion protein can be
added to the
culture at around at least 1 ng/mL, at least 1 ug/mL, or at least 1 mg/mL,
such as from
27
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
about 0.01 ug/mL to about 1 mg/mL, from about 0.10 ug/mL to about 0.5 mg/mL,
from
about 1 ug/mL to about 0.4 mg/mL. In some examples, serial dilutions are
tested. After an
appropriate incubation time (for example, about 48 to 72 hours), cell survival
or growth is
assessed. Methods of determining cell survival are well known in the art and
include, but
are not limited to, the resazurin reduction test (see Fields & Lancaster Am.
Biotechnol.
Lab., 11:48-50, 1993; O'Brien et al., Eur. J. Biochem., 267:5421-5426, 2000 or
U.S. Pat.
No. 5,501,959), the sulforhodamine assay (Rubinstein etal., J. Natl. Cancer
Inst., 82:113-
118, 1999) or the neutral red dye test (Kitano etal., Euro. J. Clin. Investg.,
21:53-58, 1991;
West etal., J. Investigative Derm., 99:95-100, 1992) or trypan blue assay.
Numerous
commercially available kits may also be used, for example the CellTiter
968AQueous One
Solution Cell Proliferation Assay (Promega). Cytotoxicity is determined by
comparison of
cell survival in the treated culture with cell survival in one or more control
cultures, for
example, untreated cultures and/or cultures pre-treated with a control
compound (typically
a known therapeutic), or other appropriate control.
[00109] Additional assays are described in, for example, Crouch et al. (J.
Immunol.
Meth. 160, 81-8); Kangas etal. (Med. Biol. 62, 338-43, 1984); Lundin etal.,
(Meth.
Enzymol. 133, 27-42, 1986); Petty etal. (Comparison of J. Biolum. Chemilum.
10, 29-34,
1995); and Cree etal. (AntiCancer Drugs 6: 398-404, 1995). Cell viability can
be assayed
using a variety of methods, including MTT (3-(4,5-dimethylthiazoly1)-2,5-
diphenyltetrazolium bromide) (Barltrop, Bioorg. & Med. Chem. Lett. 1: 611,
1991; Cory et
al., Cancer Comm. 3, 207-12, 1991; Paull J. Heterocyclic Chem. 25, 911, 1988).
Assays
for cell viability are also available commercially. These assays include but
are not limited
to CELLTITER-GLOt Luminescent Cell Viability Assay (Promega), which uses
luciferase technology to detect ATP and quantify the health or number of cells
in culture,
and the CellTiter-GloOLuminescent Cell Viability Assay, which is a lactate
dehyrodgenase (LDH) cytotoxicity assay (Promega).
[00110] Fusion proteins that confer selectivity for a specific type of
cancer may be
tested for their ability to target that specific cancer cell type. For
example, a fusion protein
comprising a specific IL-4 that targets cells displaying IL-4R Type I or Type
II can be
assessed for its ability to selectively target such cells by comparing the
ability of the fusion
protein to kill cancer cells to its ability to kill a normal cell, or a
different type of cancer
28
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
cell (e.g., one that does not express IL-4R Type I or Type II). Alternatively,
flow
cytometric methods, as are known in the art, may be used to determine if a
fusion protein
comprising a Type I or Type II receptor-specific IL-4 is able to selectively
target a specific
type of cell. Binding of a labeled antibody to the bound fusion protein will
indicate binding
of the fusion protein to the target.
[00111] Similarly, assays for measuring cell apoptosis are known in the
art.
Apoptotic cells are characterized by characteristic morphological changes,
including
chromatin condensation, cell shrinkage and membrane blebbing, which can be
clearly
observed using light microscopy. The biochemical features of apoptosis include
DNA
fragmentation, protein cleavage at specific locations, increased mitochondrial
membrane
permeability, and the appearance of phosphatidylserine on the cell membrane
surface.
Assays for apoptosis are known in the art. Exemplary assays include TUNEL
(Terminal
deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling) assays, caspase
activity
(specifically caspase-3) assays, and assays for fas-ligand and annexin V.
Commercially
available products for detecting apoptosis include, for example, Apo-ONE
Homogeneous
Caspase-3/7 Assay, FragEL TUNEL kit (ONCOGENE RESEARCH PRODUCTS, San
Diego, Calif.), the ApoBrdU DNA Fragmentation Assay (BIOVISION, Mountain View,
Calif.), and the Quick Apoptotic DNA Ladder Detection Kit (BIOVISION, Mountain
View, Calif.).
[00112] A variety of cell lines suitable for testing the candidate fusion
proteins are
known in the art and many are commercially available (for example, from the
American
Type Culture Collection, Manassas, Va.). Similarly, animal models are known in
the art
and many are commercially available.
[00113] Therapeutic Indications and Uses
[00114] The fusion proteins including IL-4R binding protein and a pro-
apoptotic
Bc1-2 family member, as described herein, can be used for a variety of
therapeutic
purposes. In general, the fusion proteins described herein can be used in the
treatment or
prophylaxis of any disease, disorder or condition which involves cells which
express an
IL-4R, and which would be benefited by inhibiting cell proliferation or
enhancing cell
death. In some embodiments, the fusion proteins described herein can be used
in the
29
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
treatment or prophylaxis of any disease, disorder or condition which involves
cells which
express a Type I or Type II IL-4R, and in which selection of one type of
receptor over the
other is useful, and which would be benefited by inhibiting cell proliferation
or enhancing
cell death.
[00115] In some embodiments, a fusion protein including a pro-apoptotic
Bc1-2
family member can be used to induce apoptosis or cell death or to treat a
disorder
associated with abnormal apoptosis or cell proliferation, such as cancer. As
used herein,
the terms "cancer," "cancerous," "hyperproliferative," or "neoplastic" refer
to cells having
the capacity for autonomous growth (e.g., an abnormal state or condition
characterized by
rapidly proliferating cell growth). Hyperproliferative and neoplastic disease
states may be
categorized as pathologic (e.g., as a deviation from normal but not associated
with a
disease state). Accordingly, by a "cancer" or "neoplasm" is meant any unwanted
growth
of cells serving no physiological function. In general, a cell of a neoplasm
has been
released from its normal cell division control, i.e., a cell whose growth is
not regulated by
the ordinary biochemical and physical influences in the cellular environment.
In most
cases, a neoplastic cell proliferates to form a clone of cells which are
either benign or
malignant. Examples of cancers or neoplasms include, without limitation,
transformed and
immortalized cells, tumours, and carcinomas such as breast cell carcinomas and
prostate
carcinomas. The term cancer includes cell growths that are technically benign
but which
carry the risk of becoming malignant. By "malignancy" is meant an abnormal
growth of
any cell type or tissue. The term malignancy includes cell growths that are
technically
benign but which carry the risk of becoming malignant. This term also includes
any
cancer, carcinoma, neoplasm, neoplasia, or tumor. The terms are therefore
meant to
include all types of cancerous growths or oncogenic processes, metastatic
tissue or
malignantly transformed cells, tissues or organs, irrespective of
histopathologic type or
stage of invasiveness. In some embodiments, a fusion protein including a pro-
apoptotic
Bc1-2 family member is not used in connection with a cancer affecting a stem
cell.
[00116] Most cancers fall within three broad histological classifications:
carcinomas, which are the predominant cancers and are cancers of epithelial
cells or cells
covering the external or internal surfaces of organs, glands, or other body
structures (e.g.,
skin, uterus, lung, breast, prostate, stomach, bowel), and which tend to
metastasize;
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
sarcomas, which are derived from connective or supportive tissue (e.g., bone,
cartilage,
tendons, ligaments, fat, muscle); and hematologic tumors, which are derived
from bone
marrow and lymphatic tissue. Examples of cancers include, without limitation,
carcinomas, sarcomas, and hematopoietic neoplastic disorders e.g., leukemia.
[00117] Carcinomas may be adenocarcinomas (which generally develop in
organs or
glands capable of secretion, such as breast, lung, colon, prostate or bladder)
or may be
squamous cell carcinomas (which originate in the squamous epithelium and
generally
develop in most areas of the body).
[00118] Sarcomas may be osteosarcomas or osteogenic sarcomas (bone),
chondrosarcomas (cartilage), leiomyosarcomas (smooth muscle),
rhabdomyosarcomas
(skeletal muscle), mesothelial sarcomas or mesotheliomas (membranous lining of
body
cavities), fibrosarcomas (fibrous tissue), angiosarcomas or
hemangioendotheliomas (blood
vessels), liposarcomas (adipose tissue), gliomas or astrocytomas (neurogenic
connective
tissue found in the brain), myxosarcomas (primitive embryonic connective
tissue), or
mesenchymous or mixed mesodermal tumors (mixed connective tissue types).
[00119] Hematopoietic neoplastic disorders include diseases involving
hyperplastic/neoplastic cells of hematopoietic origin e.g., arising from
myeloid, lymphoid
or erythroid lineages or precursor cells thereof. Preferably, the diseases
arise from poorly
differentiated acute leukemias (e.g., erythroblastic leukemia and acute
megakaryoblastic
leukemia). Additional exemplary myeloid disorders include, but are not limited
to, acute
promyeloid leukemia (APML), acute myeloenous leukemia (AML) and chronic
myeloenous leukemia (CML); lymphoid malignancies include but are not limited
to acute
lymphoblastic leukemia (ALL), which includes B-lineage ALL and T-lineage ALL,
chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell
leukemia, and Waldenstrom's macroglobulinemia.
[00120] Additional forms of malignant lymphomas include, but are not
limited to
non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult
T cell
leukemia/lymphoma (ATL), cutaneous T cell lymphoma (CTCL), large granular
lymphocytic leukemia (LGF), Hodgkin's disease and Reed-Stemberg disases.
[00121] Cancers may also be named based on the organ in which they
originate i.e.,
31
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
the "primary site," for example, cancer of the breast, brain, lung, liver,
skin, prostate,
testicle, bladder, colon and rectum, cervix, uterus, etc. This naming persists
even if the
cancer metastasizes to another part of the body, that is different from the
primary site.
Cancers named based on primary site may be correlated with histological
classifications.
For example, lung cancers are generally small cell lung cancers or non-small
cell lung
cancers, which may be squamous cell carcinoma, adenocarcinoma, or large cell
carcinoma;
skin cancers are generally basal cell cancers, squamous cell cancers, or
melanomas.
Lymphomas may arise in the lymph nodes associated with the head, neck and
chest, as
well as in the abdominal lymph nodes or in the axillary or inguinal lymph
nodes.
Identification and classification of types and stages of cancers may be
performed by using
for example information provided by the Surveillance, Epidemiology, and End
Results
(SEER) Program of the National Cancer Institute.
[00122] In some embodiments, a fusion protein including a pro-apoptotic
Bc1-2
family protein member, or a fragment thereof, can be used to treat cancers
such as gastric
carcinoma, invasive pituitary adenomas, biliary tract carcinoma, cervical
cancer,
lymphoma, melanoma, chronic lymphocytic leukemia, non-hodgkins lymphoma,
follicular
lymphoma, pancreatic cancer, colorectal cancer, colon cancer, thyroid cancer,
liver cancer,
ovarian cancer, prostate cancer, bladder cancer, renal cell carcinoma,
mesothelioma,
rhabdomyosarcoma, breast cancer, non-small cell lung cancer, head and neck
cancers, or
Kaposi's carcinoma.
[00123] In some embodiments, a fusion protein including a pro-apoptotic
Bc1-2
family protein member, or a fragment thereof, can be used to treat CNS cancers
such as
gliomas, meningeal tumours, diffuse intrinsic pontine glioma, medulloblastoma,
neuroblastoma, anaplastic astrocytoma, glioblastoma multiforme, metastatic
brain cancer,
or CNS lymphoma.
[00124] The fusion proteins can be used to treat, stabilize or prevent
cancer. Fusion
proteins can also be used in the treatment of indolent cancers, recurrent
cancers including
locally recurrent, distantly recurrent and/or refractory cancers (i.e. cancers
that have not
responded to other anti-cancer treatments), metastatic cancers, locally
advanced cancers
and aggressive cancers. In these contexts, the fusion proteins may exert
either a cytotoxic
32
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
or cytostatic effect resulting in, for example, a reduction in the number or
growth of cancer
cells, a reduction in the size of a tumor, the slowing or prevention of an
increase in the size
of a tumor, an increase in the disease-free survival time between the
disappearance or
removal of a tumor and its reappearance, prevention of an initial or
subsequent occurrence
of a tumor (e.g. metastasis), an increase in the time to progression,
reduction of one or
more adverse symptoms associated with a tumor, or an increase in the overall
survival time
of a subject having cancer.
[00125] Other examples of proliferative and/or differentiative disorders
that can be
treated using a fusion protein including a pro-apoptotic Bc1-2 family member
include
proliferative non-malignant diseases such as pulmonary fibrosis or hyperplasia
(such as
benign prostatic hyperplasia), cardiac fibrosis, or liver fibrosis;
inflammatory conditions
such as prostatitis, vernal keratoconjunctivitis, artherosclerosis, idiopathic
pulmonary
pneumonia; or autoimmune conditions such as Graves disease.
[00126] In some embodiments, a fusion protein including a pro-apoptotic
Bc1-2
family protein member, or a fragment thereof, is capable of inhibiting cell
survival,
inhibiting cell proliferation, or enhancing cell death or apoptosis. In some
embodiments,
the IL-4R binding protein-pro-apoptotic Bc1-2 family fusion protein is capable
of
inhibiting cell survival, inhibiting cell proliferation, or enhancing cell
death or apoptosis,
when compared to a suitable control, such as IL-4 alone, IL-4 joined to a non-
pro-apoptotic
Bc1-2 family protein, etc. A suitable control may also include a previously-
established
standard. Accordingly, any test or assay for determining the activity or
efficacy of an IL-
4R binding protein-pro-apoptotic Bc1-2 family fusion protein may be compared
to the
established standard and it may not be necessary to include a control for
comparison each
time. By "inhibiting cell survival" is meant decreasing (e.g., by at least
10%, 20%, 30%,
or by as much as 50%, 75%, 85% or 90% or more) the probability that a cell at
risk of cell
death will survive. By "inhibiting cell proliferation" is meant decreasing
(e.g., by at least
10%, 20%, 30%, or by as much as 50%, 75%, 85% or 90% or more) the growth or
proliferation of a cell. By "enhancing cell death or apoptosis" is meant
increasing (e.g., by
at least 10%, 20%, 30%, or by as much as 50%, 75%, 85% or 90% or more) the
probability
that a cell at risk of cell death will undergo apoptotic, necrotic, or any
other form of cell
death.
33
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
[00127] In some embodiments, a fusion protein including a pro-apoptotic
Bc1-2
family protein member, or a fragment thereof, is capable of inhibiting cell
survival,
inhibiting cell proliferation, or enhancing cell death or apoptosis by at
least 20%, 30%, or
by as much as 50%, 75%, 85% or 90% or more, when compared to a cell cultured
under
similar conditions but not contacted with the fusion protein. Suitable assays
for measuring
the inhibition of cell survival, inhibition of cell proliferation, or
enhancement of cell death
or apoptosis are described herein or known in the art.
[00128] In some embodiments, the IC50 of a fusion protein including a pro-
apoptotic
Bc1-2 family protein member, or a fragment thereof, in inhibiting cell
survival, inhibiting
cell proliferation, or enhancing cell death or apoptosis, can be in the range
from about 0.1
ng/mL to about 10,000 ng/mL, or any value therebetween, such as about 0.5
ng/mL, 1
ng/mL, 5 ng/mL, 10 ng/mL, 25 ng/mL, 50 ng/mL, 75 ng/mL, 100 ng/mL, 150 ng/mL,
200
ng/mL, 250 ng/mL, 300 ng/mL, 350 ng/mL, 400 ng/mL, 450 ng/mL, 500 ng/mL, 550
ng/mL, 600 ng/mL, 650 ng/mL, 700 ng/mL, 750 ng/mL, 800 ng/mL, 850 ng/mL, 900
ng/mL, 950 ng/mL, or 1000 ng/mL.
[00129] "Target cells" include, without limitation, neurons, lymphocytes,
stem
cells, epithelial cells, cancer cells, neoplasm cells, immune cells, non-
malignant cells of the
tumour microenvironment, hyper-proliferative cells, etc. The target cell
chosen will depend
on the disease or injury or condition the fusion protein is intended to treat.
[00130] Pharmaceutical Compositions, Dosages and Administration
[00131] Pharmaceutical compositions according to the present disclosure
can
include one or more fusion proteins and one or more non-toxic,
pharmaceutically-
acceptable carriers, diluents, excipients and/or adjuvants. Such compositions
can be
suitable for use in treatment of therapeutic indications as described herein.
[00132] If desired, other active ingredients may be included in the
compositions.
Accordingly, in some embodiments, a fusion protein including a pro-apoptotic
Bc1-2
family member can be administered in therapeutically-effective amounts
together with one
or more anti-cancer or other therapeutics. The fusion protein(s) can be
administered before,
during or after treatment with the anti-cancer or other therapeutic. An "anti-
cancer
therapeutic" is a compound, composition, or treatment (e.g., surgery) that
prevents or
34
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
delays the growth and/or metastasis of cancer cells. Such anti-cancer
therapeutics include,
but are not limited to, surgery (e.g., removal of all or part of a tumor),
chemotherapeutic
drug treatment, radiation, gene therapy, hormonal manipulation, immunotherapy
(e.g.,
therapeutic antibodies and cancer vaccines) and antisense or RNAi
oligonucleotide
therapy. Examples of useful chemotherapeutic drugs include, but are not
limited to,
hydroxyurea, busulphan, cisplatin, carboplatin, chlorambucil, melphalan,
cyclophosphamide, Ifosfamide, danorubicin, doxorubicin, epirubicin,
mitoxantrone,
vincristine, vinblastine, vinorelbine, etoposide, teniposide, paclitaxel,
docetaxel,
gemcitabine, cytosine, arabinoside, bleomycin, neocarcinostatin, suramin,
taxol,
mitomycin C, Avastin, Herceptine, fluorouracil, temozolamide, etc. The fusion
protein(s)
are also suitable for use with standard combination therapies employing two or
more
chemotherapeutic agents. It is to be understood that anti-cancer therapeutics
includes novel
compounds or treatments developed in the future.
[00133] The fusion protein can also be administered in combination with a
sensitizing agent, such as a radio-sensitizer (see for example Diehn etal., J.
Natl. Cancer
Inst. 98:1755-7, 2006). Generally a sensitizing agent is any agent that
increases the activity
of a fusion protein. For example, a sensitizing agent will increase the
ability of a fusion
protein to inhibit cancer cell growth or kill cancer cells. Exemplary
sensitizing agents
include antibodies to IL-10, bone morphogenic proteins and MAC inhibitors (see
for
example Sakariassen etal., Neoplasia 9(11):882-92, 2007). These sensitizing
agents can be
administered before or during treatment with the fusion protein. Exemplary
dosages of
such sensitizing agents include at least 1 ug/mL, such as at least 10 ug/mL,
at least 100
ug/mL, for example 5-100 ug/mL or 10-90 ug/mL. The sensitizing agents can be
administered daily, three times a week, twice a week, once a week or once
every two
weeks. Sensitizing agents can also be administered after treatment with the
fusion protein
is finished.
[00134] The fusion proteins may be used as part of a neo-adjuvant therapy
(to
primary therapy), as part of an adjuvant therapy regimen, where the intention
is to cure the
cancer in a subject. The fusion proteins can also be administered at various
stages in tumor
development and progression, including in the treatment of advanced and/or
aggressive
neoplasias (e.g., overt disease in a subject that is not amenable to cure by
local modalities
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
of treatment, such as surgery or radiotherapy), metastatic disease, locally
advanced disease
and/or refractory tumors (e.g., a cancer or tumor that has not responded to
treatment).
"Primary therapy" refers to a first line of treatment upon the initial
diagnosis of cancer in a
subject. Exemplary primary therapies may involve surgery, a wide range of
chemotherapies and radiotherapy. "Adjuvant therapy" refers to a therapy that
follows a
primary therapy and that is administered to subjects at risk of relapsing.
Adjuvant systemic
therapy is begun soon after primary therapy, for example 2, 3, 4, 5, or 6
weeks after the last
primary therapy treatment to delay recurrence, prolong survival or cure a
subject. As
discussed herein, it is contemplated that the fusion proteins can be used
alone or in
combination with one or more other chemotherapeutic agents as part of an
adjuvant
therapy. Combinations of the fusion proteins and standard chemotherapeutics
may act to
improve the efficacy of the chemotherapeutic and, therefore, can be used to
improve
standard cancer therapies. This application can be particularly important in
the treatment of
drug-resistant cancers which are not responsive to standard treatment.
[00135] In cancer, the microenvironment of a tumor contains both malignant
and
non-malignant cells. The tumor microenvironment can be identified using one or
more of
the following criteria: (a) a region comprising non-malignant cells which
share the same
physiological environment, or which are directly adjacent to malignant cells;
(b) the
extended tumor region; (c) an area of inflammation surrounding or proximal to
a tumor;
(d) an area in which the number or rate of proliferation of regulatory T cells
is elevated;
and (e) an area in which tumor-associated macrophages, dendritic cells,
myeloid-derived
suppressor cells, Th2 cells or fibrocytes are elevated. Within the context of
non-solid
tumor types, the tumor microenvironment may also be determined by the local
cell-cell
interactions between malignant cells and between malignant cells and any
adjacent or
nearby non-malignant cells. Such interactions may include, for example, cell
adhesion
events and/or paracrine effects of soluble mediators produced by one cell
(malignant or
non-malignant) on another cell (malignant or non-malignant) in the tumor
microenvironment.
[00136] The non-malignant cells in the tumor microenvironment can be
important
for tumor initiation and progression (Reynolds et al., Cancer Res., 1996,
56(24):5754-
5757). The non-malignant cells, also called stromal cells, occupy or
accumulate in the
36
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
same cellular space as malignant cells, or the cellular space adjacent or
proximal to
malignant cells, which modulate tumor cell growth or survival. For example,
non-
malignant cells that normally function to support inflammatory and immune
response can
be capable of contributing to tumor initiation or progression. Accordingly, in
alternative
embodiments, a fusion protein including a pro-apoptotic Bc1-2 family member
can be used
for inhibiting cell survival, inhibiting cell proliferation, or enhancing cell
death or
apoptosis of a non-malignant cell that expresses a Type I or Type II IL-4R in
a tumour
microenvironment. Such non-malignant cells can be immunoregulatory or
inflammatory
cells such as antigen presenting cells (e.g., macrophages, dendritic cells, B
cells) or
myeloid-derived suppressor cells (e.g., myeloid-derived monocytes and tie-2-
expressing
monocytes) present within the tumor microenvironment, and inhibition of T cell
subsets
that function to support tumor progression (e.g., regulatory T cells and Th2
helper cells)
and/or suppressing production of one or more inflammatory cytokines in a tumor
microenvironment. Among the non-malignant cells of a tumor microenvironment
are
regulatory T cells, which are observed in higher frequencies in a number of
tumors,
including Hodgkin's lymphoma, non-Hodgkin's lymphoma (Shi et at., Ai Zheng.,
2004,
23(5):597-601 (abstract only)), malignant melanoma (Viguier et al., J.
Immunol., 2004,
173(2):1444-53; Javia etal., J. Immunother., 2003, 26(1):85-93), and cancers
of the ovary
(Woo et at., Cancer Res., 2001, 61(12):4766-72), gastrointestinal tract
(Ichihara et al., Clin
Cancer Res., 2003, 9(12):4404-4408; Sasada etal., Cancer, 2003, 98(5):1089-
1099), breast
(Liyanage etal., J Immunol., 2002, 169(5):2756-2761), lung (Woo etal., Cancer
Res.,
2001, 61(12):4766-72), and pancreas (Liyanage etal., J Immunol., 2002,
169(5):2756-
2761). The regulatory T cells are recruited to the tumor site in response to
chemokines
secreted by the tumor cells. See e.g., Curiel etal., Nat. Med., 2004, 10:942-
949. An
increase in the number of regulatory T cells may also correlate with poor
prognosis (Curiel
etal., Nat. Med., 2004, 10:942-949; Sasada etal., Cancer, 2003, 98:1089-1099).
Conversely, regulatory T cells are observed to decrease following chemotherapy
(Beyer et
at., Blood, 2005, 106:2018-2025). The tumour micro-environment can also have a
higher
proportion of Th2 cells, when compared to Thl cells, which is associated with
poor
prognosis and survival. In alternative embodiments, a fusion protein including
a pro-
apoptotic Bc1-2 family member according to the invention, such as cpIL-4-Bad,
is useful
37
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
for restoring the Th1>>Th2 balance by, for example, depleting Th2 cells. In
some
embodiments, a fusion protein including a pro-apoptotic Bc1-2 family member
according
to the invention, such as cpIL-4-Bad, may be administered to a subject prior
to, or during,
chemotherapy, radiation therapy, immunotherapy, etc. to disable or
downregulate the
tumor microenvironment.
[00137] Non-malignant cells can also be fibroblasts, myofibroblasts, glial
cells,
epithelial cells, adipocytes, vascular cells (including blood and lymphatic
vascular
endothelial cells and pericytes), resident and/or recruited inflammatory and
immune (e.g.,
macrophages, dendritic cells, myeloid suppressor cells, granulocytes,
lymphocytes, etc.),
resident and/or recruited cells that are capable of giving rise to or
differentiating into any
of the above-noted non-malignant cells, and any functionally distinct subtypes
of the
above-noted cells as known in the art.
[00138] A "subject" can be a mammal in need of treatment, such as a human
or
veterinary patient (e.g., rodent, such as a mouse or rat, a cat, dog, cow,
horse, sheep, goat,
or other livestock). In some embodiments, a "subject" may be a clinical
patient, a clinical
trial volunteer, an experimental animal, etc. The subject may be suspected of
having or at
risk for having a condition characterized by cell proliferation, be diagnosed
with a
condition characterized by cell proliferation, or be a control subject that is
confirmed to not
have a condition characterized by cell proliferation, as described herein.
Diagnostic
methods for conditions characterized by cell proliferation and the clinical
delineation of
such diagnoses are known to those of ordinary skill in the art.
[00139] The composition can be a liquid solution, suspension, emulsion,
sustained
release formulation, or powder, and can be formulated with a pharmaceutically
acceptable
carrier. The composition can be formulated as a suppository, with traditional
binders and
carriers such as triglycerides. The term "pharmaceutically-acceptable carrier"
refers to a
carrier medium or vehicle which does not interfere with the effectiveness of
the biological
activity of the active ingredients and which is not toxic to the host or
subject.
[00140] Fusion proteins can be delivered along with a pharmaceutically-
acceptable
vehicle. In one example, the vehicle may enhance the stability and/or delivery
properties.
Thus, the disclosure also provides for formulation of the fusion protein with
a suitable
38
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
vehicle, such as an artificial membrane vesicle (including a liposome,
noisome, nanosome
and the like), microparticle or microcapsule, or as a colloidal formulation
that comprises a
pharmaceutically acceptable polymer. The use of such vehicles/polymers may be
beneficial in achieving sustained release of the fusion proteins.
Alternatively, or in
addition, the fusion protein formulations can include additives to stabilize
the protein in
vivo, such as human serum albumin, or other stabilizers for protein
therapeutics known in
the art. Fusion protein formulations can also include one or more viscosity
enhancing
agents which act to prevent backflow of the formulation when it is
administered, for
example by injection or via catheter. Such viscosity enhancing agents include,
but are not
limited to, biocompatible glycols and sucrose.
[00141] Pharmaceutical compositions containing one or more fusion proteins
can be
formulated as a sterile injectable aqueous or oleaginous suspension according
to methods
known in the art and using suitable one or more dispersing or wetting agents
and/or
suspending agents, such as those mentioned above. The sterile injectable
preparation can
be a sterile injectable solution or suspension in a non-toxic parentally
acceptable diluent or
solvent, for example, as a solution in 1,3-butanediol. Acceptable vehicles and
solvents that
can be employed include, but are not limited to, water, Ringer's solution,
lactated Ringer's
solution and isotonic sodium chloride solution. Other examples include,
sterile, fixed oils,
which are conventionally employed as a solvent or suspending medium, and a
variety of
bland fixed oils including, for example, synthetic mono- or diglycerides.
Fatty acids such
as oleic acid can also be used in the preparation of injectables.
[00142] In some embodiments, the fusion protein is conjugated to a water-
soluble
polymer, e.g., to increase stability or circulating half life or reduce
immunogenicity.
Clinically acceptable, water-soluble polymers include, but are not limited to,
polyethylene
glycol (PEG), polyethylene glycol propionaldehyde, carboxymethylcellulose,
dextran,
polyvinyl alcohol (PVA), polyvinylpyn-olidone (PVP), polypropylene glycol
homopolymers (PPG), polyoxyethylated polyols (POG) (e.g., glycerol) and other
polyoxyethylated polyols, polyoxyethylated sorbitol, or polyoxyethylated
glucose, and
other carbohydrate polymers. Methods for conjugating polypeptides to water-
soluble
polymers such as PEG are described, e.g., in U.S. patent Pub. No. 20050106148
and
references cited therein. In one example the polymer is a pH-sensitive
polymers designed
39
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
to enhance the release of drugs from the acidic endosomal compartment to the
cytoplasm
(see for example, Henry et al., Biomacromolecules 7(8):2407-14, 2006).
[00143] Typically vaccines are prepared in an injectable form, either as a
liquid
solution or as a suspension. Solid forms suitable for injection may also be
prepared as
emulsions, or with the polypeptides encapsulated in liposomes. The cells are
injected in
any suitable carrier known in the art. Suitable carriers typically comprise
large
macromolecules that are slowly metabolized, such as proteins, polysaccharides,
polylactic
acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid
aggregates,
and inactive virus particles. Such carriers are well known to those skilled in
the art. These
carriers may also function as adjuvants.
[00144] Adjuvants are immunostimulating agents that enhance vaccine
effectiveness. Effective adjuvants include, but are not limited to, aluminum
salts such as
aluminum hydroxide and aluminum phosphate, muramyl peptides, bacterial cell
wall
components, saponin adjuvants, and other substances that act as
immunostimulating agents
to enhance the effectiveness of the composition.
[00145] Vaccines are administered in a manner compatible with the dose
formulation. By an effective amount is meant a single dose, or a vaccine
administered in a
multiple dose schedule, that is effective for the treatment or prevention of a
disease or
disorder. Preferably, the dose is effective to inhibit the growth of a
neoplasm. The dose
administered will vary, depending on the subject to be treated, the subject's
health and
physical condition, the capacity of the subject's immune system to produce
antibodies, the
degree of protection desired, and other relevant factors. Precise amounts of
the active
ingredient required will depend on the judgement of the practitioner.
[00146] The pharmaceutical compositions described herein include one or
more
fusion proteins in an amount effective to achieve the intended purpose.
Typically,
compositions including a fusion protein containing a pro-apoptotic Bc1-2
family member
are administered to a patient already suffering from a disease, disorder or
condition
characterized by cell proliferation, or at risk for such a disease, disorder
or condition, in an
amount sufficient to cure or at least partially arrest a symptom associated
with cell
proliferation or reduce cell growth.
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
[00147] The skilled person will therefore recognize that the dosage to be
administered is not subject to defined limits. Prior to administration for
therapeutic
purposes, the dosage of the fusion protein may need to be modified or adapted
for the
particular purpose, for example the concentration of fusion protein needed for
whole body
administration may differ from that used for local administration. Similarly,
the toxicity of
the therapeutic may change depending upon the mode of administration and
overall
composition being used (e.g., buffer, diluent, additional chemotherapeutic,
etc.).
[00148] An "effective amount" of a pharmaceutical composition according to
the
invention includes a therapeutically effective amount or a prophylactically
effective
amount. A "therapeutically effective amount" refers to an amount of the fusion
protein
effective, at dosages and for periods of time necessary, that ameliorates the
symptoms of
the disease, disorder or condition to be treated. A therapeutically effective
amount of a
compound may vary according to factors such as the disease state, age, sex,
and weight of
the subject, and the ability of the compound to elicit a desired response in
the subject.
Dosage regimens may be adjusted to provide the optimum therapeutic response. A
therapeutically effective amount is also one in which any toxic or detrimental
effects of the
fusion protein are outweighed by the therapeutically beneficial effects.
Determination of a
therapeutically effective dose of a compound is well within the capability of
those skilled
in the art. For example, the therapeutically effective dose can be estimated
initially either
in cell culture assays, or in animal models, such as those described herein. A
"prophylactically effective amount" refers to to an amount of the fusion
protein effective,
at dosages and for periods of time necessary, that achieves the desired
prophylactic result,
such as delay in onset of symptoms of a neurological disorder or continued
remission of a
cancer. Animal models can also be used to determine the appropriate
concentration range
and route of administration. Such information can then be used to determine
useful doses
and routes for administration in other animals, including humans, using
standard methods
known in those of ordinary skill in the art.
[00149] Concentration of the fusion protein in the final formulation can
be at least
0.1 mg/mL, such as at least 1 ng/mL or at least 1 ug/mL or at least 1 mg/mL.
For example,
the concentration in the final formulation can be between about 0.01 ug/mL and
about
1,000 ug/mL. In one example, the concentration in the final formulation is
between about
41
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
0.01 mg/mL and about 100 mg/mL.
[00150] In some embodiments, a fusion protein including an anti-apoptotic
Bc1-2
family protein, or fragment thereof, is administered at concentrations ranging
from about
ng/mL to about 10,000 ng/mL, or any value therebetween, such as about 25
ng/mL, 50
ng/mL, 75 ng/mL, 100 ng/mL, 150 ng/mL, 200 ng/mL, 250 ng/mL, 300 ng/mL, 350
ng/mL, 400 ng/mL, 450 ng/mL, 500 ng/mL, 550 ng/mL, 600 ng/mL, 650 ng/mL, 700
ng/mL, 750 ng/mL, 800 ng/mL, 850 ng/mL, 900 ng/mL, 950 ng/mL, 1000 ng/mL, 1500
ng/mL, 2000 ng/mL, 2500 ng/mL, 3000 ng/mL, 3500 ng/mL, 4000 ng/mL, 4500 ng/mL,
5000 ng/mL, 5500 ng/mL, 6000 ng/mL, 6500 ng/mL, 7000 ng/mL, 7500 ng/mL, 8000
ng/mL, 8500 ng/mL, 9000 ng/mL, 9500 ng/mL, or 10000 ng/mL.
[00151] In some embodiments, a fusion protein including an pro-apoptotic
Bc1-2
family protein, or fragment thereof, is administered at concentrations ranging
from about
0.1 ng/mL to about 10,000 ng/mL
[00152] However, it will be understood that the actual amount of the
compound(s)
to be administered will be determined by a physician, in the light of the
relevant
circumstances, including the condition to be treated, the chosen route of
administration, the
actual compound administered, the age, weight, and response of the individual
patient, and
the severity of the patient's symptoms. The above dosage range is given by way
of example
only and is not intended to limit the scope in any way. In some instances
dosage levels
below the lower limit of the aforesaid range may be more than adequate, while
in other
cases still larger doses may be employed without causing harmful side effects,
for
example, by first dividing the larger dose into several smaller doses for
administration
throughout the day.
[00153] One of ordinary skill in the art will appreciate that the dosage
will depend,
among other things, upon the type of fusion protein being used and the type of
disorder or
condition being treated.
[00154] In general, the fusion proteins according to the present
disclosure contain
substantially human sequences and are therefore less antigenic than, for
example,
immunotoxins or other molecules that contain non-human sequences. In some
embodiments, the fusion proteins according to the present disclosure contain
at least 80%,
42
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
for example, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% human sequences.
In
some embodiments, the fusion proteins according to the present disclosure can
be
administered at substantially lower doses than for example, immunotoxins, or
native IL-4R
binding protein, such as IL-4 or IL-13.
[00155] In some embodiments, the fusion proteins may elicit some level of
antibody response when administered to a subject, which in some cases may lead
to
undesirable side effects. Therefore, if necessary, the antigenicity of the
fusion proteins can
be assessed as known in the art and/or described herein. For example, in vivo
toxic effects
of the fusion proteins can be evaluated by measuring their effect on animal
body weight
during treatment and by performing hematological profiles and liver enzyme
analysis after
the animal has been killed. The general toxicity of the fusion proteins can be
tested
according to methods known in the art. For example, the overall systemic
toxicity of the
fusion proteins can be tested by determining the dose that kills 100% of mice
(i.e.LDioo)
or kills 50% of mice (i.e. LD50) following a single intravenous injection.
Doses that are at
least about 2, 5, or 10-fold less than the LD100 or LD50 can be selected for
administration
into other mammals, such as a human.
[00156] The kinetics and magnitude of the antibody response to the fusion
proteins
described herein can be determined, for example, in immunocompetent mice and
can be
used to facilitate the development of a dosing regimen that can be used in an
immunocompetent human. Immunocompetent mice such as the strain C57-BL6 are
administered intravenous doses of fusion protein. The mice are killed at
varying intervals
(e.g. following single dose, following multiple doses) and serum obtained. An
ELISA-
based assay can be used to detect the presence of anti- fusion protein
antibodies.
[00157] Serum samples from mice can be assessed for the presence of anti-
fusion
protein antibodies as known in the art. As another example, epitope mapping
can also be
used to determine antigenicity of proteins as described in Stickler, et al.,
J.
Immunotherapy, 23:654-660, 2000. Briefly, immune cells known as dendritic
cells and
CD4+ T cells are isolated from the blood of community donors who have not been
exposed
to the protein of interest. Small synthetic peptides spanning the length of
the protein are
then added to the cells in culture. Proliferation in response to the presence
of a particular
43
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
peptide suggests that a T cell epitope is encompassed in the sequence. This
peptide
sequence can subsequently be deleted or modified in the fusion protein thereby
reducing its
antigenicity.
[00158] Therapeutic efficacy and toxicity can also be determined by
standard
pharmaceutical procedures such as, for example, by determination of the median
effective
dose, or ED50 (i.e. the dose therapeutically effective in 50% of the
population) and the
median lethal dose, or LD50 (i.e. the dose lethal to 50% of the population).
The dose ratio
between therapeutic and toxic effects is known as the "therapeutic index,"
which can be
expressed as the ratio, LD50/ED50. The data obtained from cell culture assays
and animal
studies can be used to formulate a range of dosage for human or animal use.
The dosage
contained in such compositions is usually within a range of concentrations
that include the
ED50 and demonstrate little or no toxicity. The dosage varies within this
range depending
upon the dosage form employed, sensitivity of the subject, and the route of
administration
and the like.
[00159] Administration of the fusion proteins can be intralesionally, for
instance by
direct injection directly into the apoptotic tissue site; into a site that
requires cell growth;
into a site where a cell, tissue or organ is at risk of cell death; or into a
site of
hyperproliferation or into a tumor. Alternatively, the fusion protein can be
administered
systemically. For methods of combination therapy comprising administration of
a fusion
protein in combination with a chemotherapeutic agent, the order in which the
compositions
are administered is interchangeable. Concomitant administration is also
envisioned.
[00160] Typically in the treatment of cancer, fusion proteins are
administered
systemically to patients, for example, by bolus injection or continuous
infusion into a
patient's bloodstream. Alternatively, the fusion proteins may be administered
locally, at the
site of a tumor (intratumorally). When a fusion protein is administered
intratumorally, the
administration can be via any route, e.g., locally, regionally, focally,
systemic, convection
enhanced delivery or combinations thereof.
[00161] When used in conjunction with one or more known chemotherapeutic
agents, the compounds can be administered prior to, or after, administration
of the
chemotherapeutic agents, or they can be administered concomitantly. The one or
more
44
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
chemotherapeutics may be administered systemically, for example, by bolus
injection or
continuous infusion, or they may be administered orally.
[00162] For administration to an animal, the pharmaceutical compositions
can be
formulated for administration by a variety of routes. For example, the
compositions can be
formulated for topical, rectal or parenteral administration or for
administration by
inhalation or spray. The term parenteral as used herein includes subcutaneous
injections,
intravenous, intramuscular, intrathecal, intrasternal injection or infusion
techniques. Direct
injection or infusion into a tumor is also contemplated. Convection enhanced
delivery can
also be used to administer the fusion protein.
[00163] In one example, the fusion protein can be injected into a subject
having
cancer, using an administration approach similar to the multiple injection
approach of
brachytherapy. For example, multiple aliquots of the purified fusion protein
in the form of
a pharmaceutical composition or formulation and in the appropriate dosage
units, may be
injected using a needle. Alternative methods of administration of the fusion
proteins will
be evident to one of ordinary skill in the art. Such methods include, for
example, the use of
catheters, or implantable pumps to provide continuous infusion of the fusion
protein to the
subject in need of therapy.
[00164] As is known in the art, software planning programs can be used in
combination with brachytherapy treatment and ultrasound, for example, for
placement of
catheters for infusing fusion proteins to treat, for example, brain tumors or
other localized
tumors. For example, the positioning and placement of the needle can generally
be
achieved under ultrasound guidance. The total volume, and therefore the number
of
injections and deposits administered to a patient, can be adjusted, for
example, according
to the volume or area of the organ to be treated. An example of a suitable
software
planning program is the brachytherapy treatment planning program Variseed 7.1
(Varian
Medical Systems, Palo Alto, Calif) or iPlan (BrainLab, Munich, Germany) for
convection
enhanced delivery to the brain. Such approaches have been successfully
implemented in
the treatment of prostate cancer and brain cancer among among others.
[00165] Fusion proteins can be used in inhibiting cell survival or
inhibiting cell
proliferation in the central nervous system (CNS). When the site of delivery
is the brain,
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
the fusion protein must be capable of being delivered to the brain. The blood-
brain barrier
limits the uptake of many therapeutic agents into the brain and spinal cord
from the general
circulation. Molecules which cross the blood-brain barrier use two main
mechanisms: free
diffusion and facilitated transport. Because of the presence of the blood-
brain barrier,
attaining beneficial concentrations of a given fusion protein in the CNS may
require the
use of specific drug delivery strategies. Delivery of fusion proteins to the
CNS can be
achieved by several methods.
[00166] One method relies on neurosurgical techniques. For instance,
fusion
proteins can be delivered by direct physical introduction into the CNS, such
as
intraventricular, intralesional, or intrathecal injection. Intraventricular
injection can be
facilitated by an intraventricular catheter, for example, attached to a
reservoir, such as an
Ommaya reservoir. Methods of introduction are also provided by rechargeable or
biodegradable devices. Another approach is the disruption of the blood-brain
barrier by
substances which increase the permeability of the blood-brain barrier.
Examples include
intra-arterial infusion of poorly diffusible agents such as mannitol,
pharmaceuticals which
increase cerebrovascular permeability such as etoposide, or vasoactive agents,
such as
leukotrienes or by convention enhanced delivery by catheter (CED). Further, it
may be
desirable to administer the compositions locally to the area in need of
treatment; this can
be achieved, for example, by local infusion during surgery, by injection, by
means of a
catheter, or by means of an implant, the implant being of a porous, non-
porous, or
gelatinous material, including membranes, such as silastic membranes, or
fibers. A suitable
membrane is Gliadel (Eisai Inc.).
[00167] Non-viral approaches can also be employed for the introduction of
a
therapeutic to a cell requiring modulation of cell death (e.g., a cell of a
patient). For
example, a nucleic acid molecule can be introduced into a cell by
administering the nucleic
acid molecule in the presence of lipofection (Feigner et al., Proc. Natl.
Acad. Sci. U.S.A.
84:7413, 1987; Ono et al., Neuroscience Letters 17:259, 1990; Brigham et al.,
Am. J. Med.
Sci. 298:278, 1989; Staubinger et al., Methods in Enzymology 101:512, 1983),
asialoorosomucoid-polylysine conjugation (Wu et al., Journal of Biological
Chemistry
263:14621, 1988; Wu et al., Journal of Biological Chemistry 264:16985, 1989),
or by
micro-injection under surgical conditions (Wolff et al., Science 247:1465,
1990).
46
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
Preferably the nucleic acids are administered in combination with a liposome
and
protamine.
[00168] Gene transfer can also be achieved using non-viral means involving
transfection in vitro. Such methods include the use of calcium phosphate, DEAE
dextran,
electroporation, and protoplast fusion. Liposomes can also be potentially
beneficial for
delivery of DNA into a cell. Transplantation of a fusion protein into the
affected tissues of
a patient can also be accomplished by transferring a normal nucleic acid into
a cultivatable
cell type ex vivo (e.g., an autologous or heterologous primary cell or progeny
thereof), after
which the cell (or its descendants) are injected into a targeted tissue.
[00169] cDNA expression for use in polynucleotide therapy methods can be
directed
from any suitable promoter (e.g., the human cytomegalovirus (CMV), simian
virus 40
(5V40), or metallothionein promoters), and regulated by any appropriate
mammalian
regulatory element. For example, if desired, enhancers known to preferentially
direct gene
expression in specific cell types can be used to direct the expression of a
nucleic acid. The
enhancers used can include, without limitation, those that are characterized
as tissue- or
cell-specific enhancers. Alternatively, if a genomic clone is used as a
therapeutic construct,
regulation can be mediated by the cognate regulatory sequences or, if desired,
by
regulatory sequences derived from a heterologous source, including any of the
promoters
or regulatory elements described above.
[00170] The present invention will be further illustrated in the following
examples.
EXAMPLES
[00171] EXAMPLE 1
[00172] This example describes making circularly permuted IL-4 proteins.
[00173] The coding sequence of IL-4 is designed to be reorganized creating
a new
amino terminus and a new carboxy terminus. The site of reorganization is
selected and
coding regions are developed synthetically or using the native sequence as a
template.
PCR can be used to amplify the separate coding regions and the 5' and 3' ends
of the
separate fragments are designed to overlap, thus allowing for the formation of
a new
47
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
coding sequence in which the newly generated peptide can for example encode a
first
amino acid that in the native protein may have been the 40th amino acid.
Specific examples
of making circularly permuted ligands are provided in U.S. Pat. No. 6,011,002.
[00174] The following sequence is used as a reference.
Name IL-4 Linker Toxin Description
cpIL4-PE MDTTEKETFCRAAT ASGGPE PE38KDEL Circularly
VLRQFYSHHEKDT (SEQ ID permuted human
RCLGATAQQFHRH NO: 29) IL-4 fused to a
KQURFLKRLDRNL Pseudomonas
WGLAGLNSCPVKE exotoxin
ANQSTLENFLERLK (PE38KDEL)
TIM REKYSKCSSGG via a ASGGPE
NGGHKCDITLQEIIK linker
TLNSLTEQKTLCTE
LTVTDIFAASK (SEQ
ID NO: 2).
1001751 EXAMPLE 2
[00176] cp1L-4-BAD was prepared using standard techniques and tested on IL-
4Ra-expressing cancer cells in vitro and on IL-4Ra positive xenograft tumors
in an
athymic nude mouse model, using cpIL4-PE as a reference. The results indicated
that
cpIL-4-BAD was effective at killing the cancer cells and at regressing the
tumors.
[00177] More specifically, cpIL-4-BAD fusion protein was prepared by
transducing
BL21(DE3)pLysS bacteria with chimeric plasmid cpIL-4BAD in a pET 24a
expression
vector (Figure 1). The freshly transformed bacteria were plated on LB with
kanamycin.
Colonies were picked and transferred into 1 litre of superbroth enriched with
glucose,
MgCl2 and kanamycin and the cells were induced with 1mM IPTG. The growth of
the
cells was monitored for 6 hours. IL-4-BAD fusion proteins were refolded and
purified
using a HiTrap Column followed by two rounds of a MonoS column, after which
cpIL-4-
BAD fractions were evaluated by SDS-PAGE electrophoresis. This strategy
yielded about
0.980 mg/L cp1L-4BAD at pH 6.5, and about 2.930 mg/L cp1L-4BAD at pH 6.8.
[00178] IL-4Ra positive tumor cells (U 251 cells and Daudi cells) were
plated in
48
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
quadruplicate in 6-well petri-dishes overnight in complete medium. 0.1-1000
ng/mL of
cpIL-4BAD was added and the plates were incubated for five days in a CO2
incubator at
37 C. On day 5, the plates were washed with DCPBS and the cells were detached
with
trypsin treatment. After trypsin inactivation, viable cells were counted using
the trypan
blue exclusion technique.
[00179] The results indicated that the cpIL-4BAD fusion protein killed U
251 cells
in a concentration dependent manner in vitro, with an IC50 value of about 0.6
ng/mL
(Figure 2). 100x excess of IL-4 blocked the ability of cp11-4BAD to kill the U
251 cells,
demonstrating that the cp1L-4BAD activity was specific (Figure 3). Also, the
IC50 value
rose from about 0.3 ng/mL to >1000 ng/mL in 5-day cell viability assays.
[00180] The cpIL-4BAD fusion protein killed Daudi cells in a concentration-
dependant manner in vitro, with an IC50 value of about 0.1 ng/mL (Figure 4).
100x excess
of IL-4 also blocked the ability of cpIL-4BAD to kill the Daudi cells,
demonstrating that
the cpIL-4BAD activity was specific (Figure 5). The IC50 value rose from about
0.3
ng/mL to >1000 ng/mL in 5-day cell viability assays.
[00181] The cpIL-4BAD fusion protein was also found to decrease the colony
numbers of IL-4Ra positive tumor cells in a colony formation assay. More
specifcally,
5000 U 251 cells were plated in 10 cm culture plates (6 plates in total), cpIL-
4BAD was
added and the cells were incubated for 10 days. Colonies were stained with
Crystal Blue
and counted. The results indicated that cpIL-4BAD decreased U 251 colony
numbers in a
concentration dependent manner in vitro, with an IC50 value of about 5 ng/mL
(Figure 6).
[00182] The effectiveness of the cpIL-4BAD fusion protein was assessed in
athymic
mice after the development of subcutaneous glioma tumors with U 251 tumor
cells. More
specifically, cpIL-4BAD was injected intratumourally (IT) at 100 [tg/kg (6
injections) and
intraperitoneally (IP) 100 [tg/kg (6 injections). 0.2% HAS/PBS was used as a
vehicle
control. The assessed end points were tumor size and survival. The results
indicated that
IT administration of cpIL-4BAD regressed the tumor growth significantly
compared to the
placebo control-treated animals after 6 injections. IP administration
regressed the tumors
dramatically compared to IT treated mice. Tumors in both groups of mice
recurred beyond
49
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
day 40, when the mice in control groups were euthanized for ethical reasons,
as the tumors
were of 2000 MM3 on day 36 (Figure 7). cpIL-4BAD-treated mice also survived
longer
than placebo treated mice (Figure 8).
[00183] EXAMPLE 3
[00184] Six additional IL-4Ra positive cell lines were tested for their
sensitivity to
the cpIL-4BAD fusion protein and cpIL-4PE under identical experimental
conditions. IC50
values were determined by counting the cells using the trypan blue exclusion
technique
(Table 3).
Table 3. IC50 values of IL-4Ra positive cell lines.
Cell Line Origin IC50 (namL)
cpIL-4BAD cpIL-4PE
YCUT891 Tongue 11.0 8.0
YCUM862 Oropharynx 1.1 0.6
KCCOR891 Oral Floor 0.15 9.0
KCCL871 Larynx 0.5 1.5
YCUM911 Oropharynx 0.2 4.5
KCCTCM901 Metastasis to the chest 1.0 0.7
fluid
[00185] EXAMPLE 4
1001861 IL-4BAD, cpIL-4BAD and cpS4-BAD fusion proteins were expressed and
purified. More specifically, cDNAs of IL-4BAD, cpIL-4BAD and cp54-BAD were PCR
cloned into BamITI/Xho1 sites of a pGWO7 E. co/i. expression vector (Figure
9). The
obtained vectors were verified by DNA sequencing (Figures 10A-D).
1001871 Protein expression was performed in E. col" cells. LL-4BAD, cpIL-
4BAD
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
and cpS4-BAD proteins were expressed in 1L cultures in insoluble form,
purified under
denaturing conditions using IMAC, followed by "quick dilution" protein
refolding.
Refolding by "quick dilution" generated intact proteins free of aggregates, as
determined
by non-reducing SDS-PAGE. Final sample size and concentrations were as
follows:
IL-
4BAD was about 3.5mL at 0.24 mg/mL, determined by UV280 nm (UV280 nm Abs at
lmg/m1=1.14); cp1L-4BAD was about 3.5 mL at 0.23 mg/mL, determined by UV280 nm
(UV280 nm Abs at 1 mg/mL=1.13); and cpS4-BAD was about 3.5 mL at 0.23 mg/mL,
determined by UV280 nm (UV280 nm Abs at lmg/m1=1.25). Protein was stored in a
storage buffer composition: 500 nM NaCL, 10mM Na-Phosphate, pH 7.0, 1%
glycerol, 1
[IM EDTA, 0.01% Tween 20.
[00188] BL21(DE3)pLysS-RARE2 cells were transformed with IL-4BAD, cpIL-
4BAD and cpS4-BAD protein expression constructs, plated on LB plates
supplemented
with Amp at 100 g/mL, and incubated overnight at 37 C. The next day, colonies
from the
plate were scraped and re-suspended in liquid LB medium with 100 p.g/mL of
Amp. The
cultures were then grown at 37 C, with aeration, and protein expression was
induced by 1
mM IPTG when the cell culture reached an OD600 of about 0.5. Induction lasted
for about
4 hours at 30 C. The cell pellet was then collected and stored at -20 C. 10
!IL samples of
uninduced and induced culture were lysed by boiling at 95 C for 10 minutes in
50 L, of
reducing protein loading buffer and run on an SDS-PAGE gel. Cells from a 1 mL
sample
collected at 4 hours post-induction were lysed in hypotonic buffer, sonicated
and
centrifuged for 10 minutes at 13,000 rpm. Aliquots from the soluble and
insoluble fraction
were boiled in reducing protein loading buffer and analyzed on an SDS-PAGE
gel.
Estimated expression levels observed for IL-4BAD, cp1L-4BAD proteins was more
than
50 mg/L of crude material. Estimated expression levels observed for cpS4-BAD
was more
than 50 mg/L. IL-4BAD was found to be almost completely insoluble, with some
possible
soluble form (less than 5%). cp54-BAD were mainly in the insoluble fraction.
[00189] The cell pellets from the induced cultures were lysed at room
temperature
and the inclusion bodies fraction was collected and washed with PBS-T. The
insoluble
material was solubilized in 8M Urea and bound to 3 mL Ni-charged resin. The
resin was
washed with 15 CV of wash buffer and the bound protein was eluted in 8 CV
elutions of
51
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
step gradient of imidazole in wash buffer. 7.5 [IL, from each fraction was
analyzed on a
SDS-PAGE gel. The fractions with the highest amount of IL-4BAD (about 6 mg)
and
cpIL-4BAD (about 8 mg) were combined and refolded. The remaining fractions
were
stored at -20 C.
[00190] The IL-4BAD and cpIL-4BAD fractions were combined, reduced by the
addition of 1 mM DTT and subjected to a slow step-wise dialysis against
storage buffer
(150 mM NaC1, 10 mM HEPES, pH 7.4, 0.01% Tween 20) supplemented with a
decreasing concentration of urea at each dialysis buffer change. The protein
concentration
was measured after each dialysis step by UV Spectroscopy: IL-4BAD was about
0.8 mg;
and cpIL-4BAD was about 0.45 mg. The samples were then run on an SDS-PAGE gel.
[00191] 25 [IL of each protein (-0.6 mg/mL, 200 mM Imidazole fraction) was
diluted in 1 mL of the following buffers: 20 mM HEPES, pH 7.4, 1% glycerol, 10
1.1M
EDTA, 0.01% Tween (Buffer 1); 10 mM Na-Phosphate, pH 7.0, 1% Glycerol, 10 p.M
EDTA, 0.01% Tween (Buffer 2); and PBS, pH 7.2 (Buffer 3). The samples were
stored
overnight at room temperature. The next day, the samples were spun for 10
minutes at
13,000 rpm and the presence of the pellet in each sample was observed and
recorded in
Table 2: (+++) indicates an abundant pellet; (-) indicates no visible pellet.
Table 2: IL-4BAD and cpIL-4BAD pellets in Buffers 1, 2 and 3.
Pellet after Pellet
refolding after
114-BAD cp11.4-BAD, refolding
NaCI, 100 mM Sample 1 (+++) Sample 13 (+++)
Buffer 1 NaCI, 500 mM Sample 2 (+++) Sample 14 (++)
NaCI, 20 mM Sample 3 (++) Sample 15 , (+++)
mM NaCI, 100 mM Sample 4 (-) Sample 16
(+++)
DTT Buffer 2 NaCI, 500 mM Sample 5 (+) Sample
17 (++)
NaCI, 20 mM Sample 6 (+++) Sample 18 (+++)
Buffer 3 Sample 25 (++) Sample 27
(+++)
w/o NaCI, 100 mM Sample 7 (+) Sample 19
(++)
reduci Buffer 1 NaCI, 500 mM Sample 8 (+) Sample 20 (++)
ng NaCI, 20 mM Sample 9 (-) Sample 21 (++)
agents Buffer 1 NaCI, 100 mM Sample 10 (-) Sample 22 (++)
52
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
NaCI, 500 mM Sample 11 (+) Sample 23 (+)
NaCI, 20 mM Sample 12 (+) Sample 24
(+++)
Buffer 3 Sample 26 (+) Sample 28 (-)
[00193] The samples were also analyzed on non-reducing SDS-PAGE gel.
Refolded samples were concentrated to 100 !IL using Amicon 10 kDa MWCO, spun
down,
and a 7.5 [IL aliquot of each sample was run on an SDS-PAGE gel.
[00194] The purification process was repeated using quick dilution
folding. 4 ml of
200 mM imidazole fractions containing IL-4BAD, cp1L-4BAD or cpS4-BAD was
quickly
diluted into 200 mL of refolding buffer (500 mM NaC1, 10 mM Na-Phosphate, pH
7.0 or
6.0 or 7.8, 1% Glycerol, 10 1.1M EDTA, 0.01% Tween), incubated overnight at
room
temperature, spun down for 20 minutes at 4,000 rpm at 4 C, concentrated to 3
mL using an
Amicon 10 kDa MWCO, and buffer exchanged into storage buffer (500 mM NaCl, 10
mM
Na-Phosphate, pH 7.0 or 6.0 or 7.8, 1% Glycerol, 1 pM EDTA, 0.01% Tween) using
a
DG-10 column. Final sample concentrations were as follows: 3.5 mL of IL-4BAD
at
about 0.24 mg/mL; 3.5 mL of cpIL-4BAD at about 0.23 mg/mL. The final samples
were
run on an SDS-PAGE gel.
[00195] The final concentration of cp54-BAD was about 3.5 mL at about 0.23
mg/mL. The final sample was run on an SDS-PAGE gel.
[00196] EXAMPLE 5
[00197] A pKFR4-BAD-H6 fusion protein (Figures 11A-B) was prepared as
follows. cDNA of pKFR4-BAD-H6 was PCR cloned into the NdeUXhoI sites of a pET-
21a(+) vector. The vector was then transformed into HMS174(DE3) cells and
induced
with 0.1 mM 1PTG for 3 hours. Samples were run on an SDS-PAGE gel before and
after
induction. The cells were pelleted and lysed by ultrasonication in a buffer
containing 20
mM Tris-HC1, 300 mM NaC1, 20 mM Imidazole, pH 8.0, and samples were run on an
SDS-PAGE gel.
[00198] Inclusion bodies were dissolved in a dissolving buffer of 20 mM
Tris-HC1,
53
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
300 mM NaC1, 20 mM Imidazole, 20 mM beta-ME, 7 M GuaHC1 , pH 8Ø The
supernatant was then purified by Ni2 affinity chromatography. pKFR4-BAD-H6 was
eluted by 20 mM Tris-HC1, 300 mM NaCl, 300 mM Imidazole, 8 M Urea, pH 8.0
under
reducing and non-reducing conditions. Samples were taken throughout the
purification
process.
[00199] After purification, pKFR4-BAD-H6 was dialyzed in dialysis buffer:
0.1
%TFA, 30% acetonitrile under reducing conditions and non-reducing conditions,
yielding
a concentration of about 2.67 mg/mL.
[00200] EXAMPLE 6
[00201] To evaluate the potency of fusion proteins on IL-4R-expressing
cell lines,
HH suspension cells that express Type I IL-4R, were cultured in RPMI1640 (from
Gibco)
containing 10% FBS (from Life Technologies), 2 mM L-glutamine (from Gibco) and
10
mM HEPES (from Gibco). cpS4-BAD was added to the cell suspension. The cell
suspension was poured into a 96-well Isoplate in an amount of about 1 x 104
cells/well.
The cell suspensions were incubated at 37 C in a 5% CO2 incubator for 48
hours. Before
the end of the 48-hour incubation, 100 p.Ci/mL of [31-1]-thymidine in complete
medium was
prepared and 10 1.11_, was added into each well of the culture. After 6 hours
of incubation
with [31-1]-thymidine, 50 [IL of 50% trichloroacetic acid was slowly added
into each well
and incubated at 4 C for 2 hours. The plates were then washed five times with
dH20, and
air-dried. 100 1.11_, of scintillation liquid was added to each well and the
plates were left at
room temperature overnight. The next day, the radioactivity was read in a
MicroBeta
Trilux. Data was collected and standardized using the reading from the control
well (cell
only). The background reading (blank) was subtracted from the readings of all
the wells,
and the inhibition (% inhibition) was calculated. The IC50 of cpS4-BAD was
about 126.3
ng/mL, which was about 3 times more potent than MDNA55 (cpIL4-PE; 362.4 ng/mL)
which was used as a reference.
[00202] All citations are hereby incorporated by reference.
[00203] The present invention has been described with regard to one or
more
54
Date Recue/Date Received 2022-10-26
WO 2015/042705
PCT/CA2014/050915
embodiments. However, it will be apparent to persons skilled in the art that a
number of
variations and modifications can be made without departing from the scope of
the
invention as defined in the claims.
Date Recue/Date Received 2022-10-26
